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CHAPTER 1: INTRODUCTION  
Prostate Cancer: 
	   Prostate cancer is one of the most common cancers among American men and 
is the second leading cause of death among them in the United States [1]. Prostate 
cancer is slow growing and the majority of deaths are from metastatic disease. 
Metastatic prostate cancer generally localizes in the bones and lymph nodes [2]. The 
causes leading to prostate cancer metastasis and the mechanisms by which cells 
escape from the primary site and intravasate into the circulation to spread to distant 
organs, e.g. bone, is poorly understood [2].  
Diagnosis of Prostate Cancer: 
 Recent advances in diagnostic methods have enabled detection of prostate 
cancer at an early stage thereby reducing the number of deaths from metastasis. These 
methods include the PSA test, Digital Rectal Examination (DRE), trans-rectal ultrasound 
and trans-rectal biopsy [3]. Two of the most commonly used methods for diagnosis are 
the PSA test and DRE [2, 4]. 
Blood Test for Prostate-Specific Antigen (PSA): PSA, also known, as Kallikrein is a 
serine protease enzyme that was discovered by Dr. Richard J. Ablin and has been 
approved by FDA for annual screening of prostate cancer in men of age 50 and older. 
Serum PSA levels are higher in patients who have prostate cancer compared to men 
with healthy prostates. PSA is measured from a blood sample by Enzyme Linked 
Immuno-Absorbance Assay (ELISA), where the normal level of PSA in human blood is 
4 ng/ml. Free PSA in blood beyond 10 ng/ml indicates additional tests are necessary to 
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check for cancer. As there were many false positives in some patients, PSA test is more 
of a predictive test that needs to be verified by additional tests. Success of the PSA test 
was one factor responsible for the decline in the number of deaths that occurs due to 
prostate cancer [5, 6]. 
Digital Rectal Examination: This is a physical examination of the prostate where the 
prostate is directly palpated for irregularities from inside the rectum. However, with this 
method only 10% of the gland can be examined. Furthermore performance in detecting 
abnormalities varies greatly, and agreement between examiners is low. Therefore 
additional markers are necessary to augment existing PCa tests. [2, 3, 7]. 
Prostate Cancer Pathology and Grading 
 Once diagnosed, prostate cancer is classified into different grades and stages that 
are used to predict responsiveness to a specific cancer therapy, such as radiotherapy or 
surgery. The Gleason grading system developed by Dr. Donald F. Gleason is the most 
commonly used method to grade prostate cancer tissues based on the histologic 
pattern of arrangement of cancer cells in Hematoxylin and Eosin (H&E) stained prostate 
tissue sections [8]. Gleason grades include five basic grade patterns (Figure 1.1). To 
generate a histologic score, ranging from 2 to 10, the primary and the secondary grade 
patterns are added. “Gleason grade has been linked to a number of clinical end points, 
including clinical stage, progression to metastatic disease, and survival” [6, 8, 9].  
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Figure 1.1: Gleason grading system. This was developed by Dr. Donald F. Gleason and is the 
most commonly used method to grade prostate cancer tissues based on the so called 
“architecture” of H&E-stained prostatic tissue sections [8]. 
Treatment Options: 
 There are several methods available for treating men with prostate cancer. 
These include surgery, chemotherapy, cryotherapy, hormonal therapy, radiation, High 
Intensity Focused Ultrasound (HIFU), and "watchful waiting” [10][2]. Treatment options 
vary between patients depending on the patient’s age, stage and grade of the disease. 
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The treatment that is best for one man may not be best for another, and yet another 
may have a combination of treatments [2]. 
Risks Factors for Prostate Cancer: 
Common risk factors that are associated with prostate cancer include: age, race and 
diet [2, 11].  
Age over 65: Age is the main risk factor for prostate cancer. In the United States, most 
men with prostate cancer are over 65. This disease is rare in men under 45. There is a 
racial component and African-American men should be screened earlier for prostate 
cancer at age 40 [2, 11]. 
Race: Prostate cancer is more common among African-American men than Caucasians 
or Hispanic men. It is less common among Asian and Native American men. Also the 
rate of men dying from prostate cancer has varied, depending on their race and 
ethnicity where recent data shows that, African-American men were more likely to die of 
prostate cancer than any other ethnic group. Caucasian men had the second highest 
rate of deaths from prostate cancer, followed by Hispanic, Native American, Alaskan 
Native, and Asian/Pacific Islander [12, 13].  
Diet and Prostate Cancer: Diet is also considered an important risk factor for prostate 
cancer. Epidemiologic studies have suggested that high consumption of fat and red 
meat, and lower consumption of fruits and vegetables contributes to morbidity [11, 14-
17]. Animal fat is especially rich in arachidonic acid, whose metabolites have been 
shown to affect prostate cancer progression [16, 17].  
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Arachidonic Acid Metabolism: 
 Arachidonic acid (AA) is an essential component of mammalian cell membranes 
and plays a critical role in the synthesis of eicosanoids [18]. Arachidonic acid and its 
precursor, linoleic acid, are major components in animal fats and many vegetable oils 
[17]. Arachidonic acid is mobilized by phospholipase A2 (PLA2) from cellular membrane 
glycerolipid pools in response to many stimuli such as cytokines and growth factors 
(15). Arachidonic acid is present in membrane phospholipids and is released by 
phospholipase A2 and can be oxidized by three distinct enzymes Cyclooxygenase 
(COX), Lipoxygenase (LOX), or P450 epoxygenase into three distinct pathways to form 
a variety of eicosanoids as shown in Figure 1.2 [18]. “Eicosanoids are 20-carbon lipid 
molecules derived from the enzymatic breakdown of membrane lipid precursors, chiefly 
arachidonic acid” [18]. These bioactive metabolites of arachidonic acid are potent in 
several physiological and pathological processes such as inflammation, asthma, and 
cancer [19, 20]. Lipid mediators generated by these enzymes are involved in a wide 
variety of cellular and molecular pathways, including but 
not limited to apoptosis, cell survival, proliferation, chemotaxis and senescence [19, 20]. 
Lipoxygenease Pathway:  
	   In the	  lipoxygenase pathway, AA is oxidized by several enzymes resulting in the 
formation of hydroxyeicosatetraenoic acids (HETEs), leukotrines, lipoxins, and 
hepoxilins. “The chief enzymes of the LOX pathway are the 5- LOX, 12-LOX, and 15-
LOX enzymes whose names are derived from the position in which molecular oxygen is 
inserted into the arachidonic acid backbone” [21]. 
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bioactive eicosanoids [1]. Eicosanoids are generated via the
oxidation of the 20-carbon chain present on arachidonic acid or
other related fatty acids [2]. During processes, such as
inflammation, arachidonic acid is released from the cell
membrane through the activation of phospholipase A2 [1].
Arachidonic acid is metabolized by the CYP ω-hydroxylases
to 7-, 10-, 12-, 13-, 15-, 16-, 17-, 18-, 19-, and 20-HETEs, the
principal metabolite being the pro-inflammatory 20-HETE [4].
Stimulus Phospholipid
Arachidonic acid
COX1
COX2
COX3
5-LOX
8-LOX
12-LOX
15-LOX
Epoxygenases
CYP2C
CYP2J
CYP4A
n-HETELEUKOTRIENES“PROSTAGLANDINS” EPOXYEICOSATRIENOIC ACID
MSPPOH
HET0016
Prostacyclins
PGI2
Prostaglandins
PGE2
PGD2
PGF2 Thromboxanes
TXA2
Platelet
aggregation 
Inflammation
Pain Proliferation
LT A4
LT B4
LT C4
LT D4
12-HETE
19-HETE
20-HETE
Inflammation
Vascular
functionCOX1
20-OH PGE2
20-OH PGI2
5,6-EET
8,9-EET
11,12-EET
14,15-EET
EET agonist
14, 15-EEZE
sEH sEH inhibitor
Vasorelaxation
Cardioprotection
Proliferation
Inflammation
DHET
Inflammation
Allergy
Bronchoconstriction
Cyclooxgenase (COX) Lipooxygenases (LOX) Cytochrome P450  (CYP)(87 genes in humans)
O
O
OH
HO
HO
Prostacyclins Leukotrienes C4
OH
S
COOH
CONHCH2COOH
NHCO(CH2)2CHCOOH
NH2
OH
COOH
20-HETE
O O
HO
11,12-EET
A
B
Fig. 1 a, b Bioactive eicosanoids derived from the arachidonic acid
cascade. Arachidonic acid is metabolized by three pathways—the
cyclooxygenase (COX), lipoxygenase (LOX), and cytochrome P450
(CYP) pathways. Schematic overview of major mediators and their
metabolites (blue); enzymes (black, boxed) and biological role (green).
Inhibitors (red ovals) and agonists (green ovals). HETEs Hydroxyeico-
satetraenoic acids, EETs epoxyeicosatrienoic acids, CYP cytochrome
P450 enzymes. MS-PPOH is a selective inhibitor of a subset of
epoxygenases. HET0016 is a selective inhibitor of the ω-hydroxlase
CYP4A. The sEH inhibitor (soluble epoxide hydrolase inhibitor)
increases EET levels by acting as an agonist of the EET pathway.
14,15-EEZE is a putative EET receptor antagonist. PGE2 prostaglandin
E2, PGI2 prostacyclin, LTA4 leukotriene A4, DHET dihydroxyeicosa-
trienoic acid, 20-OH PGE2 20-hydroxy-prostaglandin E2
Cancer Metastasis Rev (2010) 29:723–735 725
 
Figure 1.2: Schematic overview of major bioactive lipids derived from arachidonic acid 
metabolism by three classes of enzymes (Cyclooxygenase, Lipoxygenase and 
Cytochrome P450) into three pathways [ 2].  
 The predominant bioactive products of the 5-LOX pathway are the leukotrienes 
(LT). Leukotrienes include LTA4, LTB4, LTC4 and LTD4 [21]. LTA4 is the primary 
leukotriene formed by action of 5-LOX on AA, which is then hydrolyzed to LTB4 by 
LTA4 hydrol se [21]. Action of LTC4 synthase n LTA4 can als  ive rise to the 
cysteinyl leukotrienes, namely LTC4 and LTD4 [21, 23].  
 Another key enzyme of the LOX family is 12-LOX. The three important isoforms 
are platelet-type, epidermal, and leukocyte-type 12-LOX that act on AA to result in the 
synthesis of 12(S)-HETE [21]. It is known that 12-LOX and its product 12(S)-HETE is 
involved in the disease process of a variety of cancers including colon carcinoma, 
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melanoma, human glioma, prostate and breast cancer [18, 20]. Studies have also 
shown that 12(S)-HETE has a wide range of biological functions and has been 
implicated in prostate cancer metastasis through its action on endothelial cell retraction 
and integrin regulation [18, 24, 25]. Another key member of LOX family is 15-LOX, 
which exists as two isoforms; 15-LOX-1 and 15-LOX-2 [18, 20]. Action of 15-LOX on 
arachidonic acid gives rise to 15-HETE [21]. 
P450 Epoxygenase Pathway:  
 Cytochrome P450-dependent metabolism of AA includes two distinct pathways: 
the ω-hydroxylase and epoxygenase pathways [22]. The ω- hydroxylases of the 4A and 
4F gene families of cytochrome P450 (CYP4A and CYP4F) convert arachidonic acid to 
autacoids such as hydroxyeicosatetraenoic acids (HETEs) [22, 26].                                  
20-HETE is the principal isoform of this pathway and can be vasoconstrictive [27, 28]. 
The epoxygenase pathway occurs in several tissues including liver, kidney, and the 
cardiovascular system [26]. This latter pathway includes two enzymes, CYP2C and 
CYP2J, which generate epoxyeicosatrienoic acids (EETs) that are known to have 
vasodilatory activity [22, 26]. Guo et al. have shown that 20-HETE can stimulate 
endothelial cell proliferation and VEGF expression in vitro suggesting that CYP ω-
hydroxylase may play an important role in tumor growth and angiogenesis [29, 30]. In 
Non Small Cell Lung Cancer (NSCLC) cells, CYP ω-hydroxylase enhanced cellular 
invasion in vitro as well as angiogenesis and metastasis in vivo and significantly 
increased the expression of VEGF and MMP-9 in vitro and in vivo [29, 30].  
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Cyclooxygenase Pathway:   
	   Most prostate cancer biology has focused on the role of COX and LOX 
enzymes [18, 20, 31, 32]. Cyclooxygenase has two isoforms that differ mainly in 
regulation of their expression and tissue distribution. COX-1 is widely expressed in most 
tissues, whereas COX-2 expression is normally absent, but can be induced by 
numerous stimuli such as growth factors, TNFα and inflammation [33, 34]. COX-2 is 
over expressed in many human non-endocrine and endocrine tumors including those of 
the colon, breast, prostate, brain, thyroid, and pituitary [33, 35]. Cyclooxygenase 
catalyzes the conversion of AA into a prostaglandin intermediate, PGH2, which is in turn 
oxidized by several other enzymes that can form two classes of eicosanoid products, 
namely prostaglandins (PGI2, PGE2, PGD2, PGF2a) or thromboxanes (TXA2) (Figure-
1.3) [36-38].   
Prostaglandin E2 (PGE2) is formed by the action of prostaglandin E synthase 
(PGES) on Prostaglandin H2 (PGH2). Among the COX metabolites, PGE2 has been 
widely implicated in various steps of cancer development and progression such as 
angiogenesis, cell survival, proliferation, and chronic inflammation [21, 31, 35]. 
PGH2 can also be acted on by thromboxane synthase (TXA2S) that catalyzes its 
conversion to thromboxane A2 (TXA2), a potent vasoconstrictor and an inducer of 
platelet aggregation [39, 40] [36, 37, 41]. Additionally the enzyme prostacyclin synthase, 
antagonizes the effect of TXA2S by catalyzing the conversion of PGH2 to prostacyclin I2 
(PGI2) that opposes the action of TXA2, namely causing vasodilation and inhibiting 
platelet aggregation [42, 43]. 
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different. The dependence of the lesions on cycloox-
ygenase-1 has been established, but it is uncertain
whether the finding of lesions on endoscopy is actu-
ally predictive of the likelihood of serious gastroin-
testinal complications, such as perforation, obstruc-
tion, and bleeding. Indeed, the hemorrhagic nature
of most serious gastrointestinal end points makes it
likely that they primarily reflect the inhibition of cy-
clooxygenase-1 activity in platelets, rather than in gas-
tric mucosa. Finally, the low incidence of these events
means that many patients must be studied for pro-
longed periods of treatment to detect the differences
between drugs reliably.
 
21,22
 
The biochemical selectivity of a particular drug, as
assessed in vitro, is critically dependent on its con-
centration. One can summarize such selectivity pro-
files by plotting the drug concentrations necessary
to inhibit the activity of cyclooxygenase-2 and cyclo-
oxygenase-1 by 50 percent (Fig. 2).
 
23-26
 
 However, giv-
en the concentration dependence of these estimates,
it is not useful to attempt to discriminate between
existing NSAIDs on the basis of small differences in
biochemical selectivity with the use of terms such as
“preferential cyclooxygenase-2 inhibitor.”
How well do the results of these in vitro assays
predict selectivity when the measurements are per-
 
Figure 1.
 
 Production and Actions of Prostaglandins and Thromboxane.
Arachidonic acid, a 20-carbon fatty acid containing four double bonds, is liberated from the 
 
sn
 
2 position in membrane phospho-
lipids by phospholipase A
 
2
 
, which is activated by diverse stimuli. Arachidonic acid is converted by cytosolic prostaglandin G/H
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Figure 1.3: G neration of the prostanoids through me abolism of arachidonic cid by the 
COX pathway. In the first step of the generation of TXA2, COX-1 and COX-2 isoforms are 
responsible for the conversion of AA to PGH2. Thromboxan  synthase (TXA2S) then catalyzes 
the conversion of the COX product, PGH2 to TXA2 [44]. 
 
Thromboxane Synthase and TXA2: 
 Thromboxane synthase (TXA2S) is an ER membrane protein that belongs to the 
P450 epoxygenase family and catalyzes the conversion of PGH2 to TXA2 [45]. The 
enzyme plays a role in several pathophysiological processes including hemostasis, 
cardiovascular disease, and stroke [46]. TXA2S is a 60 KDa protein that was first 
identified as a micr somal enzyme in platelets [46, 47]. TXA2S expression is detectable 
in lung, platelets, kidney, stomach, duodenum, colon and spleen [46, 48]. Its expression 
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is reported to be closely associated with cardiovascular, renal, and inflammatory 
diseases [49].  
 TXA2 is very unstable in aqueous solution, and becomes hydrolyzed within 30s to 
the biologically inactive TXB2 [36, 50]. Due to its very short half-life, TXA2 functions as 
an autocrine or paracrine mediator in the nearby tissues surrounding its site of 
production [48]. TXA2 is responsible for multiple biological processes through the cell 
surface TXA2 receptor, or T-Prostanoid, receptor (TP) [46]. TXA2S, and TP are the two 
important components necessary for the functioning of this potent bioactive lipid 
signaling pathway [46].  
Thromboxane A2 Receptor: 
 Ushikubi et al. first purified TXA2 receptor protein from human blood platelets in 
1989 [51]. In 1991, a cDNA for the human TP receptor was originally cloned from 
placenta and the platelet-like MEG-01 cell line by Hirata et al. [52, 53]. Raychowdhury et 
al. later isolated a cDNA encoding a second isoform of the TP receptor from a human 
umbilical vein endothelial cell (HUVEC) cDNA library [53, 54]. Thus, to date there are 
two receptors for TXA2 in humans, termed TPα from human placenta and TPβ from 
endothelial cells [53, 55, 56]. In humans, these cDNAs represent alternative splice 
products of the same TXA2 receptor gene. In all other species, it is only expressed as a 
single isoform, TPα [52, 54, 57]. The physiological significance of the existence of two 
receptors for TXA2 in humans, but not in other species is still not well understood.  
Human TPα and TPβ are typical G-protein coupled receptors (GPCR) that share the 
first 328 amino acids but differ in their C-terminal tail, where TPα has a shorter C-
terminal cytoplasmic tail than the TPβ isoform (15 versus 79 residues) [52-54] (Figure-
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1.4). Ligand binding sites on the TP receptor are in its extracellular region and are 
identical in both splice variants. Therefore, differences in function between TPα and 
TPβ likely reside in the complement of G-proteins associated with their C-termini [57-
59].  
 
multiple cancers indicating the extensive nature of these
effects and the widespread clinical applicability of targeting
these pathways as adjunct therapy in cancer [30–32, 34].
2.1 Role of thromboxane A2 signaling in prostate cancer
Prostate cancer (PCa) is one of the most common cancers
among men in the USA and is the second leading cause of
death in this population [35]. Strong correlations exist
between diets high in fat (especially from red meat) and
PCa [36–38]. As red meat is rich in AA, the presence of
enzymes associated with AA metabolism might result in
increased synthesis of downstream lipid mediators. Several
metabolites of AA, such as 5-HETE and 12-HETE, have
already been studied widely for their roles in PCa [39–42].
Numerous studies demonstrate increased COX-2 mRNA
and protein expression in PCa correlate with poor prognosis
[43, 44]. TXA2 is derived from the COX product PGH2
and, as a consequence, both TXA2S and TP have long been
hypothesized to have a possible role in prostate cancer
progression.
Prostate tumor progression involves several key steps
including cell survival, cell migration, cell invasion, and
metastasis. Human PCa cells express functionally active
TXA2S and biosynthesize TXA2 [45]. As the expression of
COX-2 and COX-1 in prostate cancer has been reported
previously, Nie and colleagues investigated their role in
synthesis of TXA2 [45]. Treatment of PC-3 cells with both
COX-1 and COX-2 inhibitors reduced TXA2 synthesis by
95%, similar to the level achieved by direct TXA2S
antagonism. These data suggest that human PCa cells
express TXA2S and that both COX-1 and COX-2 are
essential for providing the substrate for TXA2S mediated
TXA2 biosynthesis in PCa cells [45]. Increased TXA2S
expression and activity in PCa cells augmented cell
migration but had minimal effect on cell cycle progression
or survival indicating that TXA2S activity might contribute
to PCa progression through modulating cell motility [45].
In a study conducted on tissue samples from 46 patients,
with well-documented histological and molecular data,
increased TXA2S and COX-2 expression were observed
in tumors. In the same study, TP expression was higher in
malignant tissues (high-grade prostatic intraepithelial neo-
plasia and cancer glands) [46]. Similarly, TXA2S mRNA
and protein expression were higher in prostate carcinomas
compared to matched normal tissues. In contrast, epithelial
cells in non-tumoral glands displayed almost non-existent
TXA2S and TP expression [46]. The degree of TXA2S
expression correlated with the severity of prostate carcinoma
lesions, with advanced stages and poorly differentiated forms
having the highest expression levels [45, 46]. Moreover, a
significant association between the expression of COX-2/
TXA2S/TP and higher Gleason score/pathologic stage of the
tumors was observed [46]. Within the cancer tissue,
expression of TXA2S and TP were localized to areas of
perineural invasion, a known mechanism by which PCa cells
penetrate the prostatic capsule and spread to other tissues.
Strong expression of TXA2S along perineural tracts might be
an indicator for its potential involvement in tumor cell
invasion and metastasis [45–47]. The enzyme was found to
be involved in motility, but not proliferation or survival, of
PCa cells [45].
Tumor cell migration is an important step in the
metastatic cascade. At this time, tumor cells leave the
primary organ, enter the circulation, and colonize distant
tissues [48]. Rho GTPases are critical for the dynamic
Fig. 2 Structures of TPα and
TPβ receptor proteins. The
TXA2 receptor (TP) is a typical
G-protein-coupled receptor
that is expressed as two different
isoforms in humans—TPα
and TPβ. TP isoforms share the
first 328 amino acids but
differ in the length of the
C-terminal cytoplasmic tail with
TPα shorter than the TPβ
isoform (15 versus 79 residues)
[24, 25]
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Figure. 1.4: Structures of TPα and TPβ Receptor Proteins. TPα and TPβ are encoded by the 
single TP receptor gene, on chromosome 19p13n3 [31], and arise by a novel differential splicing 
mechanism within exon 3, whereby nucleotides 984–1642 of the TPα mRNA behave as an 
intron (intron 2b) within the TPβ mRNA [52-54]. 
 TXA2 is responsible for multiple biological processes through its cell surface 
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receptor TP.  Previous studies have shown that activation of TP by TXA2 or its stable 
synthetic analog, U46619, will result in platelet aggregation [50], contraction of vascular 
smooth muscle cells [60] or release of prostacyclin from endothelial cells [61]. Ligation 
of TP by TXA2 can evoke the activation of multiple downstream pathways including 
phospholipase C activation and a subsequent rise in the intracellular Ca2+ 
concentration, leading to vasoconstriction and platelet aggregation [48, 57]. TXA2 has 
been implicated in the pathology of a variety of cardiovascular diseases, including 
atherosclerosis [62], stenosis after vascular injury [63], and hypertension [64] [49]. 
Distribution of Thromboxane A2 Receptor (tissues and cells) 
 TP can be found in a large number of tissues, and cell types include platelets, 
lung, vascular smooth muscle, endothelial cells, kidney, brain, spleen, thymus, 
monocytes, uterus, and placenta [46, 57, 65]. 
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Table 1: Cells in which TP receptors have been identified based on ligand binding studies 
[57, 65]. 
 
Thromboxane A2 Receptor–Ligand Interaction: 
It was previously shown that the transmembrane (TM) region of TP contributes to its 
ligand binding since point mutations of amino acids in the TM region resulted in 
diminished ligand-binding activity [66]. The second extracellular loop (eL2) of TP is 
important for ligand binging, especially amino acids Cys183 to Asp193 [67]. The NMR 
study demonstrated that Val176, Leu185, Thr186 and Leu187 in eL2 of TP are putative 
ligand contact points [68]. Point mutations within eL2 of TP indicated that Asp193 is a 
key amino acid for ligand binding (both for binding to agonist and antagonist) [69]. This 
study also reported that Phe184, Thr186 and Ser191 are key residues for antagonist 
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binding [66]. Pharmaceutical companies have successfully designed TXA2 competitive 
antagonists for TP that target this region thereby affecting its functional role.  
Agonists and Antagonists: 
 TXA2 is very unstable in aqueous solution, where it is hydrolyzed with a half-life 
of 30s to form the biologically inactive thromboxane B2 (TXB2) [36]. More stable 
functional analogs have been synthesized because of the short half-life of TXA2 and 
characterized. Notable agonists include U-46619 [70] [71] and I-BOP [72] [73]. The 
antagonists include PTA2 [74], SQ-29,548 [75], Ramatoroban (Bay U3405) [76, 77], and 
seratrodast [78, 79]. The failure of existing TXA2S inhibitors and TXA2 antagonists to 
show robust clinical benefit in treatment of cardiovascular disorders has largely been 
due to co-incident use of Nonsteroidal anti-inflammatory drugs (NSAIDs), such as 
aspirin, as part of the standard of care.  Conversely, current therapeutic regimens for 
cancer incorporate few agents from this class making TXA2S/TP antagonism an 
attractive target with potentially significant therapeutic benefit. Moreover, in contrast to 
NSAIDs, TXA2S/TP inhibitors do not prevent other COX-derived anti-tumor products 
with beneficial effects, such as PGI2, from being synthesized. 
Thromboxane A2 Receptor and its Signal Transduction 
 Stimulation of TP receptors in platelets leads to an increase in intracellular free 
calcium, activation of Phospholipase C, generation of IP3 and diacylglycerol, activation 
of protein kinase C, stimulation of myosin light chain kinase and exposure of integrin 
IIb/IIIa binding sites [53]. In platelets, stimulation of the TPα receptor isoform results in 
an increase in cAMP formation. The same observation was made with CHO and COS -
7 cells transfected with TPα [53, 58]. Ushikubi et al. showed that the presence of TPβ 
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coupled to Gαi2 in reconstituted vesicles resulted in decreased cAMP formation [80].  
 
Contribution of G proteins in TP Signaling: 
 TXA2 signaling through TPα and TPβ occurs when they couple with G proteins, 
such as Gq, G11, G12, G13, G15, G16, Gi, Gs and Gh, which in turn regulate effectors 
such as phospholipase C, guanine nucleotide exchange factor of the small G protein 
Rho (RhoGEF) and adenyl cyclase (Figure 1.5) [57, 58, 66]. Activation of TP by TXA2 
can evoke the activation of phospholipase C leading to phosphatidylinositol turnover 
and a subsequent rise in the intracellular calcium ion concentration, which in turn leads 
to vasoconstriction and platelet aggregation (Figure 1.5) [57, 66]. However signaling 
through Gq and G12/13 appears most relevant to TP function [66]. Gq couples to 
platelet TP receptors, as evidenced by increases in agonist stimulated GTPase activity 
[66]. TP-mediated morphological changes in platelets are mainly dependent on G12/13. 
Platelet aggregation by TXA2 is dependent on Gq (Figure 1.5) [81] [57-59]. 
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Figure 1.5: G protein coupling of thromboxane receptor and signal transduction 
[66]. 
 TP isoforms have both common and distinct signaling pathways depending on 
the G protein subunits bound to their C-terminal tail. Therefore, differences in function 
between TPα and TPβ must manifest due to the complement of G-proteins associated 
with it [46].  One of the major differences between the two isoforms is the cAMP 
pathway. When each TP isoform was expressed in CHO cells, IBOP, a TP agonist, 
increased intracellular cyclic AMP levels in TPα-expressing cells, but decreased cyclic 
AMP levels in TPβ expressing cells (Figure 1.5) [55]. These studies suggest that the 
coupling of TPα with Gs-stimulating adenylyl cyclase and of TPβ with Gi-inhibiting 
adenyl cyclase both induce changes in cyclic AMP levels, and this can be exploited [53]. 
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Furthermore, Gh functionally interacts with TPα, but not TPβ [82]. It has been also 
shown that TPβ, but not TPα expression is required for the inhibition of vascular 
endothelial growth factor (VEGF)-induced migration and angiogenesis [83], suggesting 
that the downstream signaling pathways differ between TP isoforms [57-59]. 
Role of Thromboxanes in Cardiovascular Disorders: 
 Both TXA2 biosynthesis and thromboxane receptor (TP) expression is elevated in 
numerous cardiovascular and inflammatory diseases [49, 56, 84, 85]. By signaling 
through its receptors, TXA2 plays a very important role in the pathogenesis of acute 
coronary artery syndrome, vessel remodeling, thrombosis, renal, pulmonary and 
atherosclerotic cardiovascular diseases, primarily through its action as a potent 
vasoconstrictor and an inducer of platelet aggregation and activation [56, 62, 79, 85-88].  
Therefore, inhibition of TXA2S and TP has become central to the therapy of many 
diseases including myocardial infarction, hypertension, stroke and renal dysfunction [89-
91]. Aspirin is the most common drug used to prevent TXA2 production. Other 
thromboxane modulators which have been either approved for therapeutic use or under 
clinical trials for the above mentioned diseases includes terbogrel [92], Ridogrel [93], 
SQ-29548 [75], Ramatoroban (Bay U3405) [76, 77], and seratrodast [78, 79]. In recent 
years, several studies revealed an additional functional role for both TXA2S and TP, 
namely in cancer progression [46, 94-103].  
Role of Thromboxanes in Cancer Progression: 
Increased COX-2 expression has been described in a variety of diseases [33, 34] 
and also documented in various cancers including pancreatic cancer [104], lung cancer 
[105-107], breast cancer [108], colon cancer [109] and prostate cancer [106, 110-112].  
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Though several reports have documented the antitumor effects of NSAIDs, it is not well 
understood how COX promotes tumorigenesis and cancer progression. As TXA2 is a 
downstream metabolite of the COX pathway, this has elicited interest as to whether 
COX-2 actions are mediated by TXA2 signaling [113]. The eicosanoid products of the 
COX pathway have dramatically different, sometimes contrasting or antagonizing, 
biological activities [114-116]. Therefore, the actual profile of the downstream COX 
metabolites is more relevant than the level of COX protein since the COX metabolites 
such as TXA2 and PGI2 have diverse and opposing functions [46].  
 One of the first study to look into the role of downstream metabolites of COX, 
such as TXA2 in cancer progression and metastasis was by Honn et al., where they had 
shown inhibition of either TXA2S or TXA2 receptor reduced cancer metastasis in vivo 
from tail vein injected B16a lung cancer cells. Inhibition of TXA2S also decreased tumor 
cell proliferation and inhibits DNA synthesis in B16 melanoma cells [116, 117].  Several 
years later, a study by Nie et al. in 2003, also indicated a functional role for TXA2S in 
prostate cancer progression. Since then, there have been several reports indicating a 
functional role for not only TXA2S but also for TP in several cancers that includes 
breast, bladder, lung and colon cancer [46, 94-103]. Cancer progression involves 
several key steps such as angiogenesis, cell survival, cell migration, cell invasion and 
metastasis, and studies have shown that both TXA2S and TP play important roles in 
one or more of these key process [46, 95, 96, 100, 118-120].    
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Role of Thromboxanes in Prostate Cancer: 
 Nie et al. had shown that human PCa cells express TXA2S and that this enzyme 
may contribute to PCa progression through modulation of cell motility [94]. As the 
expression of COX-2 and COX-1 in prostate cancer has been reported previously, data 
suggest that human PCa cells express functionally active TXA2S and that both COX-1 
and COX-2 are essential for providing the substrate for TXA2S mediated TXA2 
biosynthesis in PCa cells [94]. Increased TXA2S expression and activity in PCa cells 
augmented cell migration, but had minimal effect on cell cycle progression or survival 
[94]. Increased TXA2S expression and TXA2 biosynthesis in PCa cells highlighted 
further a possible functional role for TP in PCa tissues, as the actions of TXA2 are 
mediated by its interactions with TP receptors. 
 In a study conducted on tissue samples from 46 patients, with well-documented 
histological and molecular data, increased TP, TXA2S and COX-2 expression were 
observed in malignant tissues (High-Grade Prostatic Intraepithelial Neoplasia (HGPIN) 
[46, 97]. Similarly, TXA2S mRNA and protein expression were higher in prostate 
carcinomas compared to matched normal tissues [97].  In contrast, epithelial cells in 
non-tumoral glands displayed almost no TXA2S or TP expression [46]. Moreover, a 
significant association between the expression levels of COX-2, TXA2S, and TP and 
higher Gleason score/pathologic stage of the tumors was observed [97].  Though this 
study confirms that TP expression is higher in prostate cancer tissues, it did not identify 
which isoform, TPα or TPβ, was predominantly expressed [46]. 
 Tumor cell migration is an important step in the metastatic cascade, at which 
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time the tumor cells leave the primary organ to enter the circulation, so as to colonize 
distant tissues [121]. Prostate tumor progression involves several key steps including 
cell survival, cell migration, cell invasion and metastasis, and studies have shown that 
TXA2S or TP play a key role in either one of these processes [46]. Rho GTPases are 
critical for the dynamic changes in cell shape and adhesion that drive cell migration. Nie 
and colleagues demonstrated that the TXA2-TP signaling axis regulated cell migration 
and cytoskeleton reorganization by promoting Rho-A activation [101]. Recent studies 
have indicated that the Gα12 family of heterotrimeric G proteins (Gα12 and Gα13) is up-
regulated in PCa and that activation of Gα12 signaling, through a Rho-dependent 
pathway, promotes PCa cell invasion. Also Gα12 signaling via Rho is required for   
TXA2-stimulated invasion of PCa cells [122].  Therefore, as TP is known to couple to the 
Gα12 family of heterotrimeric G-proteins, the up-regulation of both TP and Gα12 in PCa 
suggests a possible role for TP in driving the cell migration and invasion observed in 
high grade PCa. 
 There is also a novel constitutive interaction between TPα and TPβ with the 
Protein kinase C-related kinases (PRK1) [123]. PRK1 is a RhoA effector that has been 
widely implicated in androgen-associated PCa and ovarian serous carcinomas [123]. It 
was established that PRK1 directly interacts with endogenously expressed TPα and 
TPβ in both PC3 and LNCaP cells, and that disruption of PRK1 by siRNA substantially 
impairs cell migration in response to TXA2 agonist U46619 in these cells [123].  These 
findings are all suggestive of a functional role of TP receptor in cell migration in prostate 
cancer [46]. 
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Crosstalk between Thromboxane and EGFR Signaling Pathways: 
 Mitogen-activated protein kinases (MAPK) play a central role in regulating cell 
growth and differentiation. The activation of MAPK may result from stimulation of either 
Receptor Tyrosine Kinases (RTK), which possess intrinsic tyrosine kinase activity, or G-
Protein-Coupled Receptors (GPCR) [124, 125]. The signaling pathways that link 
GPCRs to MAPK involve both receptor and non-receptor tyrosine kinases as well as 
Protein Kinase C (PKC) [126]. The Epidermal Growth Factor Receptor (EGFR) tyrosine 
kinase as an essential link in the GPCR-mediated MAPK activation in Rat-1 fibroblasts, 
HaCaT keratinocytes, primary mouse astrocytes, and COS-7 cells [127] [128, 129]. 
Studies also have shown that TP-mediated activation of MAPK signaling involves EGFR 
by two possible mechanisms: Ligand-Independent (Src kinase-dependent) [127], and 
Ligand-dependent (shedding of EGFR ligands) [130].  
Transactivation of EGFR by TP receptor in a Ligand Independent Manner: 
 Gao et al. have shown that EGFR plays an essential role in the TP-mediated 
MAPK activation in a ligand-independent manner. Activation of the Gq-coupled TP 
receptor by the TXA2 mimetic IBOP in ECV304 cells (bladder cancer cell-line) was 
found to induce ERK phosphorylation through tyrosine phosphorylation of EGFR in an 
Src dependent manner (Figure 1.6) [127]. Tyrosine kinases of the Src family are 
involved in mediating both the tyrosine phosphorylation of EGFR, and MAPK activation 
from both Gq and Gi coupled receptors [127] [124, 125]. Furthermore, TP receptor 
activation also increases Src kinase activity, which is blocked by Src Inhibitor PP1, but 
not by AG1478, indicating that Src activation occurs before phosphorylation of EGFR 
[127]. 
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Figure 1.6: Activation of MAPK pathways by TP receptor involves transactivation of 
EGFR in a Src kinase-dependent manner.  A proposed model by Gao et al., suggests that 
stimulation of TPα and TPβ by TXA2 leads to phosphorylation of ERK (ERK-P), and involves 
transactivation of EGFR in a Src-kinase-dependent manner in TPα or TPβ-transfected cells 
[127]. 
TP receptor mediated Transactivation of EGFR through the shedding of EGFR 
Ligands: 
 
 The work of Galet et al. has shown the existence of an additional mechanism by 
which TXA2 stimulation of TPα and TPβ in human aortic smooth muscle cells (hASMC) 
cells leads to EGFR transactivation resulting in phosphorylation of ERK1/2 in a ligand 
dependent manner. Transactivation of EGFR is dependent on the cleavage of pro-
Heparin-binding EGF-like growth factor (HB-EGF) by matrix metallo proteinase (MMPs) 
in response to TP receptor stimulation thereby allowing the binding of HB-EGF to its 
receptor [126]. A broad spectrum inhibitor of MMPs, i.e. BB2516 decreased ERK and 
EGFR phosphorylation in TPα or TPβ-transfected cells indicating the important role of 
MMPs in TP-mediated EGFR transactivation (Figure-1.7) [126]. They also demonstrated 
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that both TP isoforms activated ERK phosphorylation in an Src-kinase-dependent 
manner in HEK293 cells. This confirms the existence of both ligand-dependent and 
ligand-independent mechanisms of EGFR transactivation [126]. 
 
Figure 1.7: Crosstalk between Thromboxane and EGFR signaling by shedding of EGFR 
ligands by MMPs.  A proposed model by Galet et al., suggests that stimulation of TPα and TPβ 
by TXA2 results transactivation of EGFR that is dependent on the cleavage of pro-HB-EGF by 
extracellular MMPs thereby freeing HB-EGF to bind to its receptor [126]. 
 
 In another study by Uchiyama et al. TP-mediated EGFR transactivation is partially 
caused by shedding of EGFR ligands such as HB-EGF, which involves furin and ADAM 
via novel types of PKCs (PKC-δ and PKC-ε) through Gαq/11 proteins in an extracellular 
Ca2+-dependent manner [130]. Activation of TP activated the EGFR pathway by Src-
dependent phosphorylation, and also activates EGFR by causing shedding of EGFR 
ligands. These studies strengthen further the idea that TP receptor mediates EGFR 
signaling. 
  
24 
EGFR Family of Receptor tyrosine Kinases: 
 The EGFR family of RTKs consists of four members: EGFR/ErbB1, HER2/ErbB2, 
HER3/ErbB3 and HER4/ErbB4 [131-138]. All EGFR family members share a similar 
structure that consists of three regions: an extracellular ligand-binding domain, a single 
trans membrane segment, and a large intracellular domain with protein kinase activity 
(Figure-1.8) [139-144]. Upon activation by a number of EGF-like growth factor ligands, 
ErbB receptors form homo or heterodimeric complexes that, which leads to the 
autophosphorylation of cytoplasmic tyrosine residues in the kinase domain. This leads 
to activation of down-stream signaling cascades, such as the Ras activated MAPK 
pathway, and the phosphoinositide 3-kinase (PI3-K)/Akt pathway (Figure-1.8) [139-145].  
 ErbB receptors regulate multiple cellular responses, including cell proliferation, 
survival, migration, and differentiation [146]. EGFR and ErbB4 can homodimerize when 
bound to ligands, or heterodimerize with any of the other ErbB receptors, with ErbB2 
being the preferred heterodimeric partner [147]. ErbB2 and ErbB3 each require 
heterodimerization in order to transduce signals, because ErbB3 does not have an 
intrinsic kinase, while ErbB2 is not bound by any known ligand (Figure-1.8) [147]. Hence 
ErbB2 constitutively exists in the active conformation state. Therefore, it is always 
available for dimerization with other EGFR family members [147]. ErbB signaling is 
important for normal biological function, but unregulated signaling by EGFR and ErbB2 
has been shown to contribute to cancer progression [139-144]. Members of the EGFR 
family have frequently been implicated in various forms of human cancers and serve 
both as prognostic markers and as therapeutic targets [139-144]. 
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Figure 1.8: Members of Epidermal Growth Factor Receptor (EGFR) Family: The ErbB 
receptor family consists of four closely related type 1 transmembrane tyrosine kinase receptors, 
EGFR, ErbB2, ErbB3, and ErbB4. EGFR and ErbB4 have active tyrosine kinase domains and 
known ligands. ErbB3 can utilize several neuregulins as ligands, but lacks tyrosine kinase 
activity. By contrast, ErbB2 possesses an active tyrosine kinase domain, but no ligand has been 
identified [148].  
 
 
Epidermal Growth Factor Receptor: 
 
 ErbB1 was the first RTK to be sequenced by Ullrich et al. [22]. EGFR is a        
170 kDa transmembrane glycoprotein that is present on all epithelial and stromal cells 
as well as on select glial and smooth muscle cells, though not on hematopoietic cells 
[131, 141, 143]. EGFR can be activated by binding to growth factors of the EGF-family 
that are produced by the same cells that express EGFR (autocrine secretion) or by 
surrounding cells (paracrine secretion) [139, 143]. Upon binding of an extracellular 
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ligand, the receptor transforms the inactive monomers into homodimers that activate its 
intracellular tyrosine kinase domain and autophosphorylate its C-terminal tyrosine 
residues. This stabilizes the active receptor conformation and creates phosphotyrosine-
docking sites for proteins that transduce signals within the cell leading to activation of 
several downstream signaling pathways (Figure-1.9)[131, 141, 143].  
 The EGFR homodimer possesses multiple sites of tyrosine phosphorylation and 
couples to multiple downstream signaling effectors (Figure-1.9) [137, 140]. EGFR is 
most often upregulated in a wide variety of human tumors such as bladder, breast, head 
and neck, kidney, non-small cell lung, and prostate cancer, and is associated with 
advanced disease and poor clinical prognosis [141, 146, 149, 150]. Studies of various 
tumors have revealed that many express either EGFR or one of its common ligands, 
such as the epidermal growth factor (EGF), Amphiregulin (AREG) and transforming 
growth factor-α (TGFα). Some tumor cells express both the receptor and one of the 
ligands [142, 144, 150]. Activation of EGFR by its ligands either in an autocrine or 
paracrine manner has been shown to play an important role in prostate cancer 
progression from localized PCa to metastatic disease [141, 146, 149, 150].  
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Figure 1.9: EGFR tyrosine phosphorylation sites. A schematic representation of the 
EGFR homodimer binding to its ligand is shown.  Sites of cytoplasmic tyrosine (Y) 
phosphorylation are indicated, as are cytosolic effector proteins that bind to these 
phosphorylated tyrosine residues, and some of the effector signaling pathways [137, 
140]. 
EGFR Ligands: 
 EGFR family members are activated by a large group of EGF-related growth 
factors. Major EGF family members includes EGF, Amphiregulin (AREG), Epiregulin 
(EREG), Transforming Growth Factor-α (TGF-α), Heparin-binding EGF-like growth 
factor (HB-EGF), Betacellulin (BTC), Epigen and Neuregulins (NRG-1, NRG-2, NRG-3, 
NRG-4) (Table-2) (Figure-1.8) [131, 132].  Common to all these growth factors is the 
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EGF domain with six conserved cysteine residues characteristically spaced to form 
three intramolecular disulphide bridges [141, 142, 144, 150]. In general, EGF-like 
ligands are synthesized as glycosylated transmembrane precursors, which are 
proteolytically cleaved from the cell surface by MMPs to yield the mature growth factor 
[141, 142, 144, 150]. 
With respect to ErbB receptor binding, EGF-related growth factors can be divided 
into three groups (Table-2) [141]. The first group includes EGF, TGF-α and AREG, 
which bind specifically to the EGFR [141, 142, 144, 150] (Table-2). The second group 
includes BTC, HB-EGF, and EREG, which show dual specificity by binding both EGFR 
and ErbB4 [141, 142, 144, 150] (Table-2) (Figure-1.8). The third group is composed of 
the Neuregulins (NRGs) and can be divided into two subgroups based upon their 
capacity to bind ErbB3 and ErbB-4 (NRG-1 and NRG-2), or only ErbB4 (NRG-3 and 
NRG-4). None of the EGF family of peptides binds ErbB-2 [138, 141, 151-153] (Table-2) 
(Figure-1.8). 
cytoplasmic tyrosine kinase-containing domain (Olayioye et al.,
2000). The intracellular tyrosine kinase domain of ErbB
receptors is highly conserved although the kinase domain of
ErbB-3 contains substitutions of critical amino acids and
therefore lacks kinase activity (Guy et al., 1994). In contrast,
the extracellular domains are less conserved among the four
receptors, suggesting that they have different specificity in
ligand binding (Olayioye et al., 2000; Yarden, 2001; Yarden and
Sliwkowski, 2001). ErbB receptors are activated by binding to
growth factors of the EGF-family that are produced by the same
cells that express ErbB receptors (autocrine secretion) or by
surrounding cells (paracrine secretion) (Fig. 1) (Olayioye et al.,
2000; Yarden and Sliwkowski, 2001). Proteins that belong to
this family are characterized by the presence of an EGF-like
domain composed of three disulfide-bonded intramolecular
groups, which confers binding specificity, and additional
structural motif such as immunoglobulin-like domains, hepa-
rin-binding sites and glycosylation sites. With respect to ErbB-
receptor binding, EGF-related growth factors can be divided
into three groups (Table 1) (Normanno et al., 2003a; Yarden and
Sliwkowski, 2001). The first group includes EGF, transforming
growth factor α (TGF-α) and amphiregulin (AR) which bind
specifically to the EGFR. The second group includes betacellu-
lin (BTC), heparin-binding growth factor (HB-EGF) and
epiregulin (EPR), which sh w dual specificity by binding
both EGFR and ErbB-4. The third group is composed of the
neuregulins (NRGs) and an be divided in two subgroups based
upon their capacity to bind ErbB-3 and ErbB-4 (NRG-1 and
NRG-2) or only ErbB-4 (NRG-3 and NRG-4) (Carraway et al.,
1997; Chang et al., 1997; Harari et al., 1999; Zhang et al.,
1997). None of the EGF family of peptides binds ErbB-2.
2.2. Receptor activation
Binding of ligands to the extracellular domain of ErbB
receptors induces the formation of receptor homo- or hetero-
dimers, and subsequent activation of the intrinsic tyrosine
kinase domain (Fig. 1) (Olayioye et al., 2000). All possible
homo-and heterodimeric receptor complexes between members
of the ErbB family have been identified in different systems
(Olayioye et al., 2000; Gullick, 2001; Schlessinger, 2000).
Receptor activation leads to phosphorylation of specific
tyrosine residues within the cytoplasmic tail (Fig. 1). These
phosphorylated residues serve as docking sites for proteins
containing Src homology 2 (SH2) and phosphotyrosine binding
(PTB) domains, the recruitment of which leads to activation of
intracellular signaling pathways. Studies on the crystal
structures of EGFR, ErbB-2 and ErbB-3’s extracellular domains
have led to new insights in the process of ligand-induced
receptor dimerization (Cho and Leahy, 2002; Cho et al., 2003;
Garrett et al., 2003; Garrett et al., 2002; Ogiso et al., 2002). The
extracellular domain of each ErbB receptor consists of four
subdomains (I–IV). Subdomains I and III (also called L1 and
L2) have a beta helical fold and are important for ligand
binding. Moreover, direct receptor–receptor interaction is
promoted by a beta hairpin (also termed dimerization loop) in
subdomain II. In the crystal structure of the extracellular domain
of EGFR bound to EGF, the dimerization loop protrudes from
EGFR and mediates interaction with another EGFR molecule
leading to the formation of a dimer composed of two 1 :1
receptor/ligand complexes (Garrett et al., 2002; Ogiso et al.,
2002). In contrast, the structure of inactive EGFR or ErbB-3 is
characterized by intramolecular interactions between domains II
and IV (Cho and Leahy, 2002; Ferguson et al., 2003). The
structure of ErbB-2 extracellular region differs significantly
from that of EGFR and ErbB-3. In the absence of a ligand,
ErbB-2 has a conformation that resembles the ligand-activated
state with a protruding dimerization loop (Cho et al., 2003;
Garrett et al., 2003). In this conformation, domains L1 and L2
are very close and this interaction makes ligand binding
impossible, explaining why ErbB-2 has no ligand (Garrett et al.,
2003). Furthermore, these findings explain why ErbB-2 has
enhanced capacity of heterodimerization and why it is the
preferred dimerization partner for the other activated ErbB
receptors (Graus-Porta et al., 1997; Tzahar et al., 1996). Among
all possible ErbB-2-contaning heterodimeric receptor com-
plexes, the most potent signaling module in terms of cell
proliferation and in vitro transformation is represented by ErbB-
2/ErbB-3 heterodimers (Citri et al., 2003). The remarkable
signaling potency of ErbB-2/ErbB-3 heterodimers derives from
the fact that this dimer has the capacity to signal very potently
both through the ras/raf/mitogen-activated protein kinase
(MAPK) pathway for proliferation and through the phosphati-
dylinositol 3-kinase (PI3K)/Akt pathway for survival (Ben-
Levy et al., 1994; Citri et al., 2003; Prigent and Gullick, 1994).
In addition, ErbB-2/ErbB-3 heterodimers evade downregulation
mechanisms leading to prolonged signaling (Lenferink et al.,
1998; Sorkin and Waters, 1993; Worthylake et al., 1999).
2.3. ErbB mediated signaling
Signal transduction pathways are initiated when activated
ErbB tyrosine kinase receptors recruit signaling proteins, such
as Shc, Grb7, Grb2, Crk, Nck, the phospholipase Cγ (PLCγ),
the intracellular kinases Src and PI3K, the protein tyrosine
phosphatases SHP1 and SHP2 and the Cbl E3 ubiquitin ligase
(Fig. 1) (Marmor and Yarden, 2004; Yaffe, 2002). All ErbB
ligands and receptors induce activation of the ras/raf/MEK/
MAPK pathway through either Grb2 or Shc adaptor proteins
(Carpenter, 2003; Citri et al., 2003; Jorissen et al., 2003). ErbB
receptors also activate PI3K by recruitment of the p85
regulatory subunit to the activated receptors (Soltoff and
Table 1
The ErbB receptors and their cognate ligands
ErbB Receptors EGFR ErbB-2 ErbB-3 ErbB-4
Cognate ligands EGF None NRG 1 NRG 1
TGF-α NRG 2 NRG 2
AR NRG 3
EP NRG 4
BTC Tomoregulin
HB-EGF HB-EGF
BTC
EP
4 N. Normanno et al. / Gene 366 (2006) 2–16
 
Table.2: EGFR family of receptors and their ligands [154]. 
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Amphiregulin- an EGFR Ligand: 
 Amphiregulin (AREG) is a glycoprotein that is originally synthesized as a trans-
membrane precursor that undergoes ectodomain cleavage and is released as a 
secreted protein [155, 156]. EGFR is believed to be the sole cell surface receptor for 
AREG in epithelial cells, as AREG has not been shown to interact directly with other 
members of the EGFR family such as ErbB2, ErbB3 and ErbB4 [157]. AREG binds 
EGFR with a lower affinity than EGF, and induces receptor autophosphorylation and 
downstream activation of the ERK signaling cascade [156, 158]. AREG mRNA is 
expressed in many normal tissues including the placenta and ovary, where it is 
abundant, as well as in the skin, testis, pancreas, spleen, kidney, lung, breast, and 
gastrointestinal tract [159]. 
 Several studies identified an active cAMP-Responsive Element (CRE) in the 
AREG promoter [160, 161]. Other conserved response elements have been identified in 
the human AREG promoter such as the Serum Responsive Element (SRE), the highly 
conserved Specificity Protein-1 element (SP1), the WT-1 responsive element (WRE) 
and the TATA box that all may have roles in regulation of AREG expression [156, 159, 
162-166].  AREG can also be regulated by the EGFR itself, where activation of EGFR 
leads to AREG expression in several cell types [155] [163, 165, 167]. For instance, 
stimulation of EGFR in prostate stromal cells with mitogenic levels of EGF and HB-EGF 
increased AREG mRNA expression more than 15-fold [166]. However, the specific 
pathway leading from EGFR activation to AREG transcription has not been elucidated 
prior to our study. Similar to EGFR, AREG also has been associated with several types 
of human cancer [155, 158, 168, 169].  
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Role of EGFR and their ligands in Prostate Cancer: 
EGF family members and their membrane receptor, the EGFR are involved in the 
pathogenesis of different tumors, including prostate cancer [170, 171]. Overexpression 
of EGF family members and their receptors results in the progression of normal prostate 
epithelial cells to a hyper proliferative cancer cell which is a key step in the multi-step 
process of development of prostate cancer [171, 172]. Changes in gene expression of 
growth factors and the corresponding changes in their receptor signaling pathways in 
epithelial and stromal cells, contributes to enhancing tumor cell growth, survival, 
migration and invasiveness [173, 174].  
Studies have confirmed the important role played by the EGFR-driven autocrine 
pathway in prostate cell growth, as it has been shown that prostate cancer cells express 
the EGFR in vitro and in vivo, and that TGF or EGF are potent mitogens for prostate 
cancer cells [154, 171]. Activated EGFR signaling may induce the stimulation of distinct 
mitotic cascades, including those of the MAPK, PI3K/Akt, and Phospholipase-C (PC) 
signaling pathways These in turn participate in the stimulation of proliferation, survival, 
motility and invasion of PCa [174]. There are a number of mechanisms by which growth 
factors of the EGF family, such as EGF, AREG, and TGF-α could contribute through 
autocrine and paracrine mechanisms to prostate cancer cell growth and proliferation 
[154, 158]. The enhanced expression of EGFR and its ligands, EGF, TGF-α, HB-EGF 
and AREG, has been reported to correlate with high grades of PCa malignancies [158, 
174]. 
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Role of Amphiregulin in Prostate Cancer: 
 AREG has been studied extensively for its role in breast cancer progression but 
there have been few studies about its possible involvement in prostate cancer until now 
[155, 168, 169]. Previous studies showed increased expression of AREG in both 
androgen-dependent and independent PCa cell lines [157, 175].  
 One of the first hints of a possible role for AREG in PCa was in a study by Sehgal 
et al. where it was shown that expression of AREG message and peptide in both 
androgen-sensitive and androgen-independent prostate cancer cell-lines.  Androgen-
dependent PCa cells, such as LNCaP cells, do express amphiregulin mRNA and 
peptide and this expression is elevated by androgenic stimulation [157]. Furthermore, 
TGF-α stimulation of EGFR induces AREG expression in LNCaP cells suggesting the 
mechanism of androgen-induced AREG expression is dependent on EGFR signaling. 
Therefore androgenic effect of AREG synthesis may occur through androgen 
upregulation of the EGFR expression [157].  
   Another study by Torring et al. has shown a selective upregulation of some 
ligands belonging to the EGF family in androgen-independent prostate cancer cell lines. 
Expression of mRNA for the ligands TGF-α, AREG, HB-EGF and EREG were increased 
10 to 100 fold in androgen-independent cells and as compared to LNCaP and 
PNT1A cells (Immortalized normal prostate epithelium) [175]. Similar results were 
obtained when examining the protein levels as confirmed by ELISA [175]. 
Bostwick et al. analyzed prostate tissue sections from 93 prostate cancer 
patients with pathologic stage T2N0M0 intermediate to high-grade (Gleason 6 and 
higher, by design) and found that AREG expression in prostate increases progressively 
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from benign epithelium to PIN and to prostate cancer. They were able to conclude that 
increased expression of AREG might contribute to the development of prostatic 
adenocarcinoma [158]. There have not been any studies looking further into the 
mechanisms that result in increased AREG expression in both androgen-dependent and 
independent cell lines. We have revealed herein a link between TP receptor signaling 
and AREG in prostate cancer. 
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Statement, Hypothesis and Specific aims: 
Statement and Rationale: 
  Most of the work performed on TP receptor in prostate cancer thus far has 
not focused on which of the two TP isoforms is indeed responsible for TP’s role in 
prostate cancer. Previous studies have indicated different functional roles for both TP 
isoforms [46, 83]. In lung cancer, TPα is thought to promote angiogenesis [176], 
Whereas TPβ expression promotes increased proliferation, migration, and invasion in 
bladder cancer cells. It is over-expressed in bladder cancer patients and associated with 
poorer prognosis in those patients [99]. Expression status of TP isoforms is largely 
uncharacterized in prostate cancer cells and tissues.  One of the objectives of this study 
is to profile TP isoform expression in prostate cancer cells and tissues, and determine 
their functional contribution in prostate cancer. 
 As previous studies had shown that the TPα receptor isoform could promote 
angiogenesis by up regulating VEGF in the lung cancer cell line A549 overexpressing 
TPα receptor [176], we initially focused on whether TP signaling could promote VEGF 
expression and subsequent angiogenesis in PCa cells.  
  Activation of endogenous TP in DU145 cells by TXA2 agonist led to an increase 
in VEGF expression as expected, and revealed for the first time, a novel link to the 
expression of amphiregulin (AREG) (1.5 Fold increase) in response to TP receptor 
stimulation. AREG is a specific ligand of EGFR that activates its downstream signaling 
pathways such as the MAP kinase pathways. We also looked at effect of TPα 
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stimulation on the predominant ligand for EGFR namely EGF, and found no effects 
(Figure- 1.10).  
 
 
Figure 1.10: TP receptor activation in DU145 cells increased expression of AREG, a 
ligand for EGFR. DU145 cells were serum starved and treated with IBOP 50nM (A) or ETOH 
(B) for 16 hrs. Before the conditioned medium was collected to measure the impact of TP 
receptor signaling on angiogenesis modulators. IBOP activation of TP receptor increased VEGF 
expression (2 fold) as well as expression of AREG (1.5 fold). 
       TP receptor activation can lead to transactivation of EGFR through 
phosphorylation in a both ligand dependent (HB-EGF) or ligand independent (Src 
kinase) manner thereby implicating TP receptor as a regulatory point in the signaling 
pathways that are stimulated by EGFR [127] [126]. Both TP and EGFR are highly 
expressed in PCa and this has been shown to play a role in its progression [46, 101, 
174]. Previous studies also have found increased expression of AREG in prostate cells 
and tissues but the specific pathways leading to AREG expression have not yet been 
elucidated [157, 158, 175]. Increased expression of AREG in response to TP stimulation 
can lead to an alternate mechanism of EGFR activation in PCa cells. To the best of our 
knowledge, this is the first study to explore the direct link between TP signaling and 
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AREG expression in prostate cancer or any other cancer. As both TP receptor and 
TXA2S enzyme are expressed in a wide range of cells and tissues including PCa 
tissues and endothelial cells [46, 94, 101], increased expression of AREG in response 
to TP receptor stimulation could lead to constitutive activation of EGFR signaling that 
could increase tumor growth and progression. These findings led us to hypothesize that 
the functional role of TP in PCa progression is mediated through activation of EGFR 
signaling brought about by overexpression of its ligand, AREG.  
Hypothesis 
TP Receptor signaling plays a role in prostate cancer by promoting AREG activation of 
EGFR signaling. 
Specific Aims: 
n Characterization of thromboxane receptor isoforms in PCa cell lines (in vitro) and 
human tissues (in vivo). 
n Determine whether stimulation of TP lead to AREG and EGFR overexpression 
and activation of downstream signaling pathways. 
n Determine the functional implications of TP activation in PCa invasion, tumor 
growth and angiogenesis in vivo   
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CHAPTER-2: MATERIALS AND METHODS 
Materials and Reagents: 
 TXA2 agonist (I-BOP) and TXA2 antagonist (SQ29548, BM567) were purchased 
from Cayman Chemicals (Ann Arbor, MI). PKA inhibitor H89, MEKK inhibitor U0126, 
EGFR inhibitor AG1478, Src Inhibitor PP2 were obtained from Calbiochem (San Diego, 
CA). EGFR inhibitor Gefitinib was kindly provided by the laboratory of Dr. Mustapha 
Kandouz (Department of Pathology, Wayne State University). AMPK inhibitor 
Compound-C was purchased from Millipore (Billerica, MA). Other chemicals were 
obtained from Sigma–Aldrich (St. Louis, MO). RPMI-1640 culture medium and heat-
inactivated fetal bovine serum (FBS) were purchased from Hyclone (Thermo Fisher, 
Rockford, IL). Human PCa cells PC3, DU145 and RWPE1 cells were supplied and 
validated by the American Type Culture Collection (ATCC, Manassas, VA) and PC3M 
Cells were obtained from Dr. Isaiah J. Fidler (University of Texas, MD Anderson Cancer 
Center, Houston, TX).  ECL Western blotting detection system was purchased from 
Thermo Scientific (Rockford, IL) as were the horseradish peroxidase (HRP)-linked goat 
anti-mouse and -rabbit IgGs. 	  
Cell Culture:  
 PC3, DU145, PC3M and LNCaP cells were grown in RPMI (Hyclone 
Laboratories, Inc., Logan, UT) containing 10% FBS at 37°C in 5% CO2 incubators.  
RWPE-1 cells were grown in Keratinocyte Serum-Free Medium (K-SFM) that contained 
two growth factors - 0.05 mg/ml BPE and 5 ng/ml EGF. Cell lines were frequently 
monitored for mycoplasma contamination by mycoplasma PCR detection kit (Sigma–
Aldrich, St. Louis, MO). 
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Generation of Stable Transfectants:  
 PC3 cells were transfected with plasmids encoding TPα (PC3-TPα), TPβ (PC3-
TPβ) or pcDNA 3.1 empty vectors (PC3-Neo) using the TransIT transfection reagent for 
prostate (Mirus Bio LLC, Madison, WI) as per the manufacturer’s instructions. After 48h, 
cells were grown for selection with G418 (400µg/ml) over two weeks. Clones expressing 
high levels of TPα were pooled for total protein isolation as were empty vector control 
cells (Neo). PC3-TPα and PC3-Neo cells were maintained in RPMI-1640 with 10% FBS 
in the presence of 0.2 mg/ml of G418 (Geneticin, Life Technologies, Grand Island, NY). 
Real time PCR was done with TP receptor isoform specific Taqman probes (Life 
Technologies, Grand Island, NY) to validate stable transfectants. 
Antibodies: 
 Rabbit polyclonal antibodies to human TPα and TPβ were kindly provided by Dr. 
Anthony Ashton (University of Sydney, Sydney, Australia). Rabbit polyclonal antibodies 
to Pan TP were purchased from Cayman Chemicals or GeneTex, Inc. (Irvine, CA). 
Rabbit monoclonal antibody specific to EGFR, ErbB2, ErbB3, ErbB4, p-ERK, ERK, p-
SRC, SRC, p-AMPK, AMPK and CD31 were from Cell Signaling Technology, Inc. 
(Danvers, MA). Antibody specific for beta-Actin was purchased from Millipore (Billerica, 
MA). Horseradish peroxidase (HRP)-linked goat anti-mouse and rabbit IgG were 
supplied by Thermo Fisher (Rockford, IL). 
Primer Design and RT-PCR:  
 The gene specific primers for human TPα and TPβ and GAPDH were ordered 
from Invitrogen. Thermo cycling PCR conditions: 95 °C for 2 min (Hot Start), (95°C for 
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30s, 60°C for 30s, 72°C for 45s) for 40 cycles. Corresponding PCR products were run 
on a 1.6% Agarose gel with Ethidium bromide and pictures of the gel were taken under 
UV illumination using a Flour Chem Alpha-Imager Imaging system (Santa Clara, CA). 
Table 3: List of Human specific primers used for RT-PCR                          
For-Forward      Rev-Reverse 
Primer Sequence 
TP-For [54] 5'- TGTTTCCGGCCCACAAACATTA -3' 
TP-Rev [52] 5'- GATACCCAGGTAGCGCTCTGA -3' 
TP-For 5'- CCTTCCTGCTGAACACGGTCA -3' 
TP-Rev 5'- GATATACACCCAGGGGTCCAG -3' 
TPα-For [177] 5'- TTCCTGCTGAACACGGTC -3' 
TPα-Rev [177] 5' -CGGAGCGCTGCGTGAGCT-3' 
TP-For [99] 5’-ACGGAGAAGGAGCTGCTCATCT-3’ 
TPα-Rev [99] 5’-CCAGCCCCTGAATCCTCA-3’ 
TPβ-Rev [99]  5’-CAAAAGGAAGCAACTGTACCCC-3’ 
GAPDH-For 
 
5’-GAGTCAACGGATTTGGTCGT-3’ 
 
GAPDH-Rev 
 
5’-TTGATTTTGGAGGGATCTCG-3’ 
 
B-Actin-For 
 
5’-GGACTTCGAGCAAGAGATGG-3’ 
 
B-Actin-Rev 
 
5’-AGCATGTGTTGGCGTACAG-3’ 
 
 
Real-time PCR Taqman Gene Expression Assay: 
 Total RNA was isolated from sub confluent cells (60-80% confluent) using 
Nucleospin-2 kit (Macherey-Nagel, Inc., Bethlehem, PA) following the manufacturer’s 
protocol and reverse-transcribed into cDNA using the ABI High Capacity RT Kit (Life 
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Technologies, Grand Island, NY). For real time detection of target gene expression, 
TaqMan® Gene Expression Assays (Life Technologies, Grand Island, NY) were used. 
Taqman Gene expression assays for TPα and TPβ were performed with custom 
designed probes made with the help of ABI Primer Express software (Life Technologies, 
Grand Island, NY). The GAPDH housekeeping gene internal control was a commercial 
assay (Life Technologies, Grand Island, NY). PCR was performed using Applied 
Biosystems 7500 Fast Real-Time PCR System in a total reaction mixture of 20 μl 
containing 25 ng of cDNA, 1 x ABI TaqMan PCR Master Mix, and 1.25 μl of 
probe/primers mixture (TaqMan® Gene Expression Assays). After denaturation at 95 °C 
for 10 min, 40 cycles were performed at [95 °C for 10 s, 60 °C for 1 min] (universal 
cycling conditions as per the manufacturer). The values for ΔΔCT were determined and 
final relative expression analyses were performed using 2 –ΔΔCT (ΔΔCt = ΔCtsample – 
ΔCtreference) as described previously [178]. 
SYBR Green Assay (AREG, EGF, EGFR, CD31, IL6, ErbB2, ErbB3, ErbB4): 
 Total RNA was isolated from sub confluent cells (70-80% confluent) (Nucleospin-
2, Macherey-Nagel, Inc., Bethlehem, PA) and reverse-transcribed into cDNA using the 
ABI High Capacity RT Kit (Life Technologies, Grand Island, NY). Primers were designed 
then synthesized by Invitrogen (Life Technologies, Grand Island, NY) or purchased from 
Real Time Primers (Elkins Park, PA). Real- time PCR was performed in 10 ul reactions 
using 96-well plates, 10-25 ng cDNA, and the 2X SYBR Green PCR Master Mix (Life 
Technologies, Grand Island, NY). Reactions were performed in triplicate using the 
Applied Biosystems ABI 7500 real-time PCR machine (Life Technologies, Grand Island, 
NY). 
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Table 4: List of primers used for Real-time PCR SYBR Green assay 
For-Forward      Rev-Reverse 
Primer Sequence 
AREG-For [167] 
 
5’-GTGGTGCTGTCGCTCTTGATA-3’ 
 
AREG-Rev [167] 
 
5’-ACTCACAGGGGAAATCTCACT-3’ 
 
EGFR-For 
 
5’-CTCAGCCACCCATATGTACC-3’ 
 
EGFR-Rev 
 
5’-CGTCCATGTCTTCTTCATCC-3’ 
 
GAPDH-For 
 
5’-GAGTCAACGGATTTGGTCGT-3’ 
 
GAPDH-Rev 
 
5’-TTGATTTTGGAGGGATCTCG-3’ 
 
B-Actin-For 
 
5’-GGACTTCGAGCAAGAGATGG-3’ 
 
 
 
 
B-Actin-Rev 
 
5’-AGCATGTGTTGGCGTACAG-3’ 
 
VEGFA-For 
 
5’-AGACACACCCACCCACATAC-3’ 
 
VEGFA-Rev 
 
5’-TGCCAGAGCCTCTCATCTCC-3’ 
 
EGF-For [167] 5’-CGCAGGAAATGGGAATTCTA-3’ 
 
EGF-Rev [167] 
 
5’-TCCACCACCAATTGCTCATA-3’ 
 
IL6 For 5’-AGCGCCTTCGGTCCAGTTGC-3’  
IL6 Rev 5’-GTGGCTGTCTGTGTGGGGCG-3’ 
 
IL8 For 5’-TAGCAAAATTGAGGCCAAGG-3’ 
 
IL8 Rev 5’-AGCAGACTAGGGTTGCCAGA-3’ 
 
CD31 For 5’-ATTGCAGTGGTTATCATCGGAGTG-3’ 
 
CD31 Rev 5’-CTCGTTGTTGGAGTTCAGAAGTGG-3’ 
 
EREG-For [167] 5’- CTGCCTGGGTTTCCATCTTCT3 -3’ 
 
 
 
EREG-Rev [167] 5’- GCCATTCATGTCAGAGCTACACT -3’ 
 
 
 
 
 
 
ErbB2-For 
 
5’-'CAGGCACCGCAGCTCATCTA-3’ 
 
ErbB2-Rev 
 
5’-TCCCAGGTCACCATCAAATACATC-3’ 
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ErbB3-For 
 
5’-CCCAGCATCTGAGCAAGGGTA-3’ 
 
ErbB3-Rev 
 
5’-TTTAGGCGGGCATAATGGACA-3’ 
 
ErbB4-For 
 
5’-TTTAGGCGGGCATAATGGACA-3’ 
 
ErbB4-Rev 
 
5’-CCAGGTAGACATACCCAATCCAGTG-3’ 
 
 
SDS-PAGE and Western Blotting 
Cells were extracted in cell lysis buffer, and proteins were loaded on 10% SDS-
PAGE gels and transferred onto nitro-cellulose membranes. Blots were then probed 
with indicated antibodies and developed by enhanced chemi-luminescence (Pierce, 
Thermo Fisher, Rockford, IL) according to the manufacturer’s instructions.  
Tissue cDNA Arrays: 
 
  Commercial cDNA arrays containing representative sets of normal and 
cancerous human tissue cDNAs (TissueScan™) were purchased from Origene 
Technologies, Inc. (Rockville, MD) and used as per manufacturer’s instructions. 
Cell Treatments: 
 
 For treatments, cells were plated in complete growth medium in 100 mm cell 
culture dishes until they are 50-70% confluent. After 24-48 hrs, spent medium was 
aspirated and replaced in serum-free medium for serum starvation overnight. Inhibitors 
were dissolved either in DMSO or ethanol, diluted in serum free medium, and added to 
the cells at appropriate concentrations for a given amount of time. Once the cells were 
pre-treated at appropriate concentrations with the inhibitors (EGFR inhibitors- AG1478, 
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gefitinib, AMPK inhibitor- Compound-C, PKA inhibitor-H89), TXA2 agonist I-BOP (50 
nM) was dissolved in ethanol and added to the cells in serum-free medium for the 
indicated times. 
 
Measurement of cAMP: 
Following treatment with I-BOP or antagonist, media samples from cultured cells 
were collected and stored at -80o C for 1-2 weeks before its assayed. The cAMP 
enzyme immunoassay (EIA) kit was purchased from Cayman Chemical (Ann Arbor, MI) 
and used according to the manufacturer’s instructions. 
Antibody Array: 
 The relative levels of expression of 55 angiogenesis-related proteins were 
simultaneously detected using the commercial angiogenesis array (Catalog No: 
ARY007) (R&D Systems, Minneapolis, MN). DU145 cells and PC3 transfectants were 
cultured in 100 mm dishes, serum-starved overnight, and subsequently treated with 
either IBOP (50nm) or ETOH (Vehicle) for 18hr as described.  Conditioned culture 
medium was then screened by antibody array for angiogenesis related proteins as per 
manufacturer’s instructions. 
Modified Boyden Chamber Cell Invasion Assay 
 Cell invasion assays were done in modified Boyden chambers fitted with 8-µm 
transwell filters as described [179]. PC3 parental or transfected cells were seeded in the 
top of transwells of the 24 well plates at a density of (2x105 cells) / (0.5 ml of 1% BSA in 
RPMI medium with ETOH, IBOP or SQ29548). Fetal bovine serum at 1% was used as a 
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chemo attractant in the bottom chambers.  After 18 h, residual, non-migrating cells on 
the upper side of the membranes were removed using Kim-wipes, and the membranes 
were fixed and stained according to manufacturer’s instructions for the Diff Quick 
staining kit (IMEB, Inc., San Marcos, CA).  Five fields of 100 cells, from random areas 
were counted. 
Animal Model and in vivo Studies:  
 All animal procedures were performed in accordance with the NIH and 
institutional guidelines established for the Department of Laboratory Animal Research 
(DLAR) at Wayne State University. Male aythymic NCr nude mice were purchased from 
Taconic Farms, Inc. (Germantown, NY).  A total of 2 X 106 PC3-TPα cells or PC3-Neo 
control cells in 200 µl of HBSS were injected sub cutaneous (s.c.) into the right flank of 
4-6-week-old male NCr nude mice (Six mice per group).  Tumor measurements were 
made using a vernier caliper, and tumor volume was calculated using the formula: 
Volume = (width)2 x length/2 [180]. 
Mice were sacrificed six to seven weeks after injection, and tumors were 
resected for further analysis [181]. Resected tumors were weighed and split into 10% 
formalin for immunohistochemistry and in Ambion’s RNAlater reagent (Life 
Technologies, Grand Island, NY) (frozen at -80oC) for subsequent RNA isolation.  
Immunohistochemistry 
 Serial sections from formalin-fixed, paraffin-embedded (FFPE) tissues were 
processed for immunohistochemistry analysis of CD31 and ki67 through core services 
provided by University Pathology Research Services (Wayne State University and 
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Barbara Ann Karmanos Cancer Institute, Detroit, MI) 
Matrigel Implantation Assay for Tumor Cell-induced Angiogenesis. 
 
 The Matrigel implantation assay was performed as described by Ito et al. [182] 
with the following modifications. Male SCID mice were purchased from Taconic Farms 
(New York, NY). A total of 2 X 106 PC3-TPα cells or PC3-Neo control cells in 100 µl of 
HBSS were mixed with 300 µl of Matrigel BME (Trevigen, Gaithersburg, MD) and 
injected s.c. into the right flank of 4-6-week-old male SCID mice (six mice per group). 
Mice were sacrificed 12 days after injection and dissected to expose the implants for 
recording [183].  
Measurement of AREG in Culture Media: 
 Cells were cultured in 6-well plates for measuring secreted AREG and other 
angiogenic cytokines. Cells were plated at a density of 2 x 105 cells per well of a 6-well 
plate. After 24 h, cells were serum starved overnight and then treated with TP agonists, 
antagonists and chemical inhibitors. Following treatment, spent medium was collected 
and the levels of AREG were determined using ELISA immunoassay kits from Ray 
Biotech (Norcross, GA), based on manufacturer’s instructions. 
Statistical Analysis: 
 Student's t test (two tailed) was used to analyze the difference between two 
groups. Differential P values <0.05 were considered significant.  
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CHAPTER-3: TPα-MEDIATED OVER EXPRESSION OF AMPHIREGULIN IS 
MEDIATED BY AMP-ACTIVATED PROTEIN KINASE (AMPK) 
Prostate cancer cells express TPα receptor: 
Though the existence of two TP isoforms was known as early as 1994, most of 
the earlier studies on TP did not distinguish the functional roles between the two 
isoforms in cardiovascular disorders and cancer progression [46, 53, 58, 66]. However 
recent findings suggest a novel role for TPβ in cancer progression especially in bladder 
cancer [99]. TPα might play a role in tumor growth by promoting angiogenesis in lung 
cancer [176], whereas TPβ expression promotes increased rate of proliferation, 
migration, and invasion in bladder cancer cells and over-expressed in bladder cancer 
patients and associated with poorer prognosis in those patients [99, 184]. In our earlier 
studies, where we have shown TP receptor plays a role in cell motility by activating 
Rho-A in prostate cancer was documented using antibodies/probes that bind the N-
terminal domain that is common to both TP receptor isoforms. Expression status of TP 
receptor isoforms and downstream signaling in response to TXA2 binding is largely 
uncharacterized in prostate cancer cells and tissues.  In this study, we first want to 
determine which TP isoform is expressed in prostate cancer cell lines and tissues.  
 To evaluate the potential role of TP receptors in prostate cancer, prostate 
epithelial cells and PCa cells were screened so as to identify which receptor isoforms 
are present and to determine their expression levels.  RT-PCR (Figure 3.1) and 
immunoblots (Figure 3.2) on whole cell extracts of the prostate cancer cell lines PC3, 
DU145, PC3M and LNCaP, revealed that these PCa cells only express the TPα 
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receptor isoform and not the TPβ receptor isoform. Real-time PCR data also indicated 
that DU145 had the highest level of TPα expression (10-11 fold) followed by PC3 (3-4 
fold) and PC3M (3 fold) compared to RWPE1 or PREC cells (Figure 3.3). TPα 
expression in LNCaP cells was similar to RWPE1 cells. These data reveal that TPα 
expression is higher in PCa cells compared to prostate epithelial cells, and that of the 
cell lines tested, DU145 had the highest expression levels of this isoform.  
 
Expression profile of TPα (mRNA) receptor in PCa cell-lines with TP isoform 
specific Primer sets (RT-PCR) 
 
A: TP isoform specific Primer set-1	  
B: TP isoform specific Primer set-2 
Figure 3.1: Screen for expression of TPα receptor in prostate cancer cell lines by 
RT-PCR. Expression of TPR was verified in several PCa cell lines such as PC3, DU145, PC3M 
and LNCaP cells and prostate epithelial cells (RWPE1) using RT-PCR. cDNA from PCa cell 
lines was analyzed with two sets of isoform specific primers designed to detect: TPα, or TPβ (A, 
B). PCR products were validated as TPα by sequencing. Non-RT samples (samples in which no 
reverse transcriptase was added) were used as Negative controls. Recombinant TPα and TPβ 
plasmids were used as positive controls (PC) for TP expression as indicated. Shown here is a 
representative result from three independent experiments. 
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A: Expression profile of TPα (protein) receptor in PCa cell-lines (Immunoblot) 
	  	  	  	   	  	  	  	   	  
B: Expression profile of TPβ (protein) receptor in PCa cell-lines (Immunoblot) 
	  	  	  	  	  	  	   	    
Figure 3.2: Screen for expression of TPα in prostate cancer cell lines by immunoblot. 
Expression of TPR was verified in several PCa cell lines: PC3, DU145, PC3M and LNCaP cells 
using Western blot. Total cell lysates prepared from these cell lines were probed with isoform 
specific TP antibodies that can detect TPα (A) and TPβ (B). Recombinant TPα protein 
expressed in SF-9 cells using baculovirus system was used as the positive control for TPα, 
[185] and HUVEC cell lysates served as the positive control for TPβ. β-Actin served as a 
loading control. The asterisks in A and B indicate non-specific bands. Shown here is a 
representative result from three independent experiments. 
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Figure 3.3: TPα expression was high in PCa cells compared to prostate epithelial cells. 
Real-time PCR was done to compare the expression of TPα mRNA levels between PCa cell 
lines (PC3, DU145, PC3M and LNCaP) and normal prostate epithelial cells (RWPE1, PREC). 
Expression of TPα was higher among the PCa cells when compared with prostate epithelial 
cells (RWPE1, PREC). Among the PCa cell lines, DU145 cells expressed the highest levels of 
endogenous TPα mRNA expression. Values expressed represent the mean fold change ± SEM, 
compared to PREC cells and is derived from three experiments normalized in each case to 
GAPDH gene expression. Similar results were observed in a further two independent 
experiments. 
 
Functional status of TPα receptor expressed in PCa cells: 
 The multiplicity of effects by TXA2 stems from its receptor isoforms TPα and TPβ 
coupling to several and distinct G-protein subunits leading to differences in function 
between the two isoforms. TPα receptor isoform binds to Gs subunit thereby stimulating 
adenylate cyclase, resulting in increased levels of the second messenger cAMP, 
whereas TPβ receptor isoform binds to Gi subunit and inhibits adenylate cyclase, 
thereby reducing cAMP levels [66]. Therefore, the differential response by two TP 
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isoforms in terms of second messenger cAMP accumulation can be used as a tool to 
confirm the expression and functional status of TPα expression in PCa cells.	  Our data 
demonstrates that cAMP levels are higher in DU145 cells compared to PC3, PC3M and 
LNCaP cells which aligns with our earlier PCR and Immunoblotting results (Figure 3.4). 
Although PC3 and PC3M cells exhibit expression of TPα protein and mRNA, the level of 
cAMP accumulation in response to IBOP was lower in these cells compared to DU145 
cells.  
 
Figure 3.4: Endogenous TPα expression in PCa cells can elicit a functional response in 
terms of second messenger. To verify whether TPα expression was enough to elicit a 
functional response, PC3, DU145, PC3M and LNCaP cells were treated with vehicle (ETOH) 
and agonist (IBOP) alone or pretreated with antagonist (SQ29548) before addition of agonist for 
20min, and the effect on cAMP synthesis was measuredby cAMP specific Enzyme 
ImmunoAssay (EIA). Results were DU145 had higher cAMP levels in response to IBOP when 
compared with other PCa cells. The results shown are mean ± standard deviation of triplicate 
wells, *p <0.05, **p <0.01; Student’s t test. This experiment was repeated at least three times 
with similar results. 
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Data-mining analysis confirms increased expression of TPR in Human PCa 
tissues  
          TPα plays a critical role in tumor growth, angiogenesis, invasion and inflammation 
[46, 176, 186, 187].   Moreover, expression of TXA2S, a rate-limiting enzyme for TXA2 
biosynthesis, is significantly up regulated in prostate cancer tissues and correlates 
positively with aggressiveness of the disease based on Gleason score [94]. In a study 
by Dassasse et al., significant association between the expression levels of COX-2, 
TXA2S, and TP and higher Gleason score/pathologic stage of the tumors was observed 
[97]. Increased TP expression in PCa tissues documented in this study was done using 
antibodies that bind to the common domain of TP, hence did not provide sufficient 
information about which of the two TP isoforms is predominantly expressed [46].  
To further examine the expression of TP isoform in prostate tumor tissues, we 
have performed data mining analysis for TP expression in the cBio Cancer Genomics 
Portal from Memorial Sloan-Kettering Cancer Center (MSKCC) that has published the 
most comprehensive genomic prostate cancer database available to date [188, 189].  
Several important observations resulted from these analyses, namely that TP receptor 
expression appeared to be upregulated in 19% of prostate cancer patients studied 
(n=85) (Figure 3.5), and was higher in PCa tissues compared to normal patient samples 
(Figure 3.5). If the Z-score threshold is lowered to 1.5, then TP expression appeared to 
be up regulated in 31% (n=26) of prostate cancer patients studied. However, the 
MSKCC studies also do not discriminate between the TPα and TPβ isoforms as the 
probes designed were for the common domain of TP [188].  
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Figure 3.5: Database search using Memorial Sloan-Kettering Cancer Center 
genomics database indicates that TPR expression is amplified in prostate carcinoma. TP 
expression is upregulated in 19% (14 samples) of total PCa samples (n=85) tested by 
microarray analysis with a Z-Score threshold of 2 that is statistically significant. Microarray 
analysis for TP receptor was done with probes that were designed for the common domain of 
TP and hence do not discriminate between the TPα and TPβ isoforms (n=85) [188] 
 
TPα expression correlates positively with aggressiveness of prostate tumors. 
All the work done so far showing increased expression of TP in PCa does not 
discriminate between the two TP isoforms.  We have shown that the PCa cell lines do 
only express the TPα isoform and not the TPβ isoform.  Since we know that TP is 
overexpressed in PCa tissues based on our database analysis, we hypothesized that it 
might be the TPα that is up regulated. Human PCa tissue was profiled for TPα utilizing 
commercial cDNA expression arrays that included representative samples of both 
  
52 
normal and prostate cancer tissues. Tissue cDNAs of each array were synthesized from 
high quality total RNAs from pathologist-verified tissues, normalized and validated with 
ß-actin in two sequential qPCR analyses.  The manufacturer provided these with clinical 
information and QC data. As there were no isoform-specific Taqman probes available 
for TPα and TPβ through ABI, the arrays were screened with custom probes that were 
designed using ABI Sequence detection software. Utilizing the accompanying clinical 
information TPα expression levels were associated with grades of different tissue 
samples based on Gleason scores [8] (Figure 3.6).  
The TPα isoform was elevated in higher grade, more aggressive prostate cancer 
seen in patients with a Gleason score greater than 7 (n = 9) versus Gleason 7 (n = 21) 
or Gleason 6 and below (n = 11) and matched normal tissues (n=8) (Figure 3.6). Based 
on the difference in primary and secondary patterns, the sum Gleason score 7 can be 
depicted as GS (4+3) or GS (3+4), where the primary grade must be >50% of the total 
cancer observed, and the secondary grade must be <50% but at least 5% of the 
observed cancer [9].  Therefore, even within the same Gleason score differences in 
gene expression are known to exist [9].  A significant finding from these data was that 
TPα expression was elevated in GS7 (4+3) (n=7) compared to GS7 (3+4) (n=17), which 
suggests that differences in TPα expression between primary and secondary patterns 
(Figure 3.6) can potentially be exploited as a biomarker for discriminating GS7 subtypes 
when making prognostic determinations.  It also implicates TPα as a therapeutic target. 
Collectively, the data-mining results and the data from qPCR analysis of human tissue 
arrays make a strong case for the association of TPα expression with the 
aggressiveness and progression of prostate tumors.  
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Figure 3.6: TPα expression levels correlate with grades of different cancer tissues that 
are classified based on its Gleason scores. Real-time PCR for TPα was done on Human 
Prostate Cancer tissue cDNA arrays using custom designed TPα specific taqman assay probes. 
The TPα isoform was elevated significantly in higher grade, more aggressive prostate cancer 
seen in patients with a Gleason score greater than 7 (n=9). TPα expression is elevated 
significantly in GS7 (4+3) (n=7) compared to GS7 (3+4) (n=17), suggesting stratification of TPα 
expression between primary and secondary patterns. Values expressed represent the mean 
fold change ± SEM, compared to Normal prostate tissues and is derived from two experiments 
normalized in each case to β-Actin gene expression. 
 
Overexpression of TPα receptor in PC3 cells: 
 To further understand whether TPα signaling mediates increased expression of 
AREG, that might be responsible for its functional role in PCa, we used two different 
Cell line models: 1. Wild-type DU145 cells (High endogenous TPα expression, Low 
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TXA2S expression) 2. PC3 cells overexpressing TPα. PC3 cells do express 
thromboxane synthase (TXA2S) and are a widely used model for in vivo studies. While 
PC3 cells appeared to express endogenous TPα, the level of expression was 
insufficient to elicit functional responses of TPα signaling such as cAMP activation and 
phosphorylation of ERK compared to DU145 cells. In order to increase the expression 
of TPα in PC3 cells to elicit better functional responses, we stably transfected TPα 
plasmid in PC3 cells to examine the effect of TPα overexpression. 
 Stable trasfectants were generated and confirmed by Real-time PCR with TPα-
specific taqman assay probes (Figure 3.7A), and by Western blotting (Figure 3.7B). TPα 
transfected PC3 cells became responsive to 50 nM I-BOP induction of cAMP synthesis 
(Figure 3.7C). Whereas, minimal activation of cAMP was measured in control PC3-Neo 
cells (Figure 3.7C). These data demonstrated that the IBOP-responsive phenotype of 
DU145 cells could be recapitulated in PC3 cells expressing ectopic TPα. 
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3.7 B: Over-expression of TPα receptor (protein) in PC3 cells (Immunoblot) 
 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
 
 
Figure 3.7: Over expression of TPα receptor in PC3 cells.  PC3 cells were transfected with 
TPα or TPβ expression plasmids, or empty vector (pcDNA 3.1) transfectants referred to as PC3-
TPα, PC3-TPβ and PC3-Neo were tested for over expression using: real-time PCR with 
Taqman gene expression probes specific for TPα (A); Values expressed represent the mean 
fold change ± SEM, compared to vector control and is derived from three experiments 
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normalized in each case to GAPDH gene expression. Similar results were observed in a further 
two independent experiments. Western blotting was done with antibodies specific for TPα and 
platelets cell lysates were used as positive control for TPα (B). The asterisks in B indicate non-
specific bands (B) Immunoblotting for each protein was performed at least three times using 
independently prepared lysates, and representative data from one such experiment are shown. 
The functional status of TPα receptor was verified by measuring cAMP accumulation by cAMP 
Enzyme Immunoassay (EIA)(C) The results shown are mean ± standard deviation of triplicate 
wells, **p <0.01; Student’s t test. This experiment was repeated at least three times with similar 
results. 
 
Activation of TPα signaling promotes overexpression of AREG in PC3 cells over 
expressing TPα: 
 Subsequently, PC3 prostate cancer cells expressing various levels of TPα were 
employed to examine the role of TPα in prostate cancer progression. We treated PC3-
Neo cells, PC3-TPα transfectants with either ETOH (Vehicle) or TXA2 agonist IBOP for 
16hrs and conditioned medium was collected for further analysis. Supernatants were 
screened for growth factors such as AREG in response to TXA2 signaling using a 
commercial antibody array (R&D Systems, Minneapolis, MN). In comparison to PC3-
Neo cells, PC3-TPα transfectants responded to IBOP activation of TPα by 
overexpressing AREG (Figure 3.8 A-D).  
 To verify the findings of elevated levels of AREG expression in PC3-TPα 
transfectants from the antibody array, ELISA for AREG was performed on the 
conditioned medium collected earlier from PC3 transfectants. Our results confirmed a 
higher secretion of AREG (5 fold) by the PC3-TPα cells in response to IBOP compared 
to vector control cells (PC3-Neo) (Figure 3.8E). Pretreatment with TXA2 antagonist 
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SQ29548 before addition of IBOP inhibited the increase in AREG expression and levels 
were comparable to ETOH treated cells (Figure 3.8E). Using Real-time PCR, the effect 
of TPα stimulation (IBOP) or inhibition (SQ29548) on AREG mRNA expression was 
tested more directly. The results indicate that AREG mRNA levels increased 6 fold in 
response to IBOP compared to ETOH treatment (Figure 3.8F). Pretreatment with TXA2 
antagonist SQ29548 before addition of IBOP inhibited the increase in AREG mRNA and 
levels were comparable to ETOH treated cells (Figure 3.8F).  
 To verify the findings from the TPα transfected cells, wild-type DU145 cells were 
treated with either ETOH (Vehicle) or TXA2 agonist IBOP or TXA2 antagonist SQ29548 
for 16hrs. Elevated levels of AREG expression both at the protein (ELISA) and mRNA 
levels (1.5 fold) in response to IBOP were also confirmed by in DU145 cells (Figure 3.8 
G, H). These findings proved that TPα does play a direct role in increased expression of 
Amphiregulin, a ligand for EGFR in prostate cancer cells. 
3.8 A-D: Effect of TPα stimulation by IBOP on AREG (protein) expression in                       
PC3 transfectants (Antibody Array) 
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Figure 3.8: Activation of TPα in PC3 cells over expressing TPα increases AREG, a ligand 
for EGFR. PC3-TPα and PC3-Neo cells were serum-starved overnight followed by treatment 
with ETOH (A, C) or IBOP (B, D). Conditioned medium was collected and screened by an 
angiogenesis antibody array. Activation of TPα by IBOP in PC3-TPα cells led to an increase in 
AREG expression levels but had little effect on EGF expression levels. PC3-TPα and PC3-Neo 
transfectants were serum-starved overnight and were treated either with ETOH or IBOP (50 nM) 
only, or they were pretreated with SQ29548 (10 µM) for 30 min before addition of IBOP. 
Conditioned medium was collected and cDNA isolated from the cell lysates. Data from Real-
time PCR (F) and ELISA (E) also confirms the increase in expression of AREG mRNA and 
protein expression in PC3-TPα cells treated with IBOP when compared with ETOH or SQ29548 
treated cells. Similar results were obtained with parental DU145 cells when treated with IBOP 
(G, H). Real-time PCR values expressed represent the mean fold change ± SEM, compared to 
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vector control and are derived from three experiments normalized in each case to GAPDH gene 
expression. Similar results were observed in a further two independent experiments. The ELISA 
results shown are mean ± standard deviation of triplicate wells, *p <0.05, **p <0.01; Student’s t 
test. This experiment was repeated at least three times with similar results 
 
Activation of TPα signaling had little effect on EGF expression in PC3 cells over 
expressing TPα: 
 We also looked at the effect of TPα receptor on EGF, which is the predominant 
ligand for EGFR, and did not find any change in EGF levels (Figures 3.8 A, B, C, D). To 
determine whether TPα receptor stimulation could lead to increased expression of EGF 
mRNA, we did Real-time PCR on cDNA samples from PC3-TPα transfectants treated 
with vehicle (ETOH), agonist (IBOP) or antagonist (SQ29548). We did not find any 
change in EGF mRNA expression in response to IBOP by Real-time PCR in PC3-TPα 
transfectants (Figure 3.9A). Similar results were obtained in parental DU145 cells that 
express higher levels of endogenous TPα (Figure 3.9B). These results indicate that 
activation of TPα by IBOP selectively upregulates AREG expression at the level of 
protein and mRNA but has little effect on EGF expression.  
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Figure 3.9: Activation of TPα in PC3-TPα transfectant cells over expressing had little 
effect on expression of EGF, the predominant ligand for EGFR: PC3 transfectants (A) and 
DU145 cells (B) were serum starved overnight and cells were treated with ETOH or IBOP (50 
nM) only or pretreated with SQ29548 (10 µM) for 30m before addition of IBOP. After 16 hrs. of 
treatment, cells were lysed in RNA lysis buffer for total RNA isolation. Expression of EGF mRNA 
in PC3-TPα (A) and DU145 cells (B) was minimally affected by treatment with IBOP. Values 
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expressed represent the mean fold change ± SEM, compared to vector control cells and is 
derived from three experiments normalized in each case to GAPDH gene expression. Similar 
results were observed in a further two independent experiments. 
AREG produced through activation of TPα receptor is functional and can 
phosphorylate EGFR in PC3 cells: 
 AREG selectively binds to EGFR, following dimerization of EGFR, which leads to 
dimerization of the receptor itself as either a homodimer or as a heterodimer with other 
EGFR family members. Subsequently EGFR undergoes phosphorylation at specific 
tyrosine residues within the intracellular domain that in turn activates downstream 
signaling pathways such as MAP kinase [ERK-1/2]. Therefore, we sought to determine 
whether the AREG that was induced in response to TPα receptor stimulation in PC3 
transfectants was functional. We assayed AREG from PC3-TPα conditioned medium for 
its ability to bind EGFR and mediate phosphorylation at tyrosine residue (pY1068).  
 To test whether this led to subsequent activation of ERK1/2, we performed 
following addback experiments. Conditioned medium was collected from PC3-Neo cells 
or PC3-TPα transfectants treated with IBOP alone (PC3-TPα+IBOP, PC3-Neo+IBOP) 
for 16hrs.  To determine if TPα mediated AREG production made a difference in the 
phosphorylation of EGFR or ERK1/2, we compared immunoblots of cells treated with 
CM from PC3-TPα to that of CM from PC3-Neo cells. We also performed the addback 
experiments in parental PC3 cells that have endogenous EGFR but have lower TPα 
receptor levels. To avoid any trans activation of EGFR involving endogenous TPα 
receptor, PC3 cells were pretreated with TXA2 antagonist SQ29548 or ETOH for 30 
minutes before addition of IBOP-treated-conditioned medium collected from PC3-TPα 
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transfectants. Whole cell lysates were prepared and subsequently analyzed for 
phosphorylation of EGFR and downstream targets such as ERK1/2 (Figure 3.10). 
 Our results support an active role for TPα receptor driven AREG production that 
leads to AREG activation of EGFR at pY1068 (Figure 3.10). Our results also support 
that AREG in the conditioned medium collected from PC3-TPα cells not only binds to 
EGFR leading to its phosphorylation but can activate downstream signaling pathways 
such as MAP kinase pathway as evident by phosphorylation of ERK1/2 (Figure 3.10). 
Therefore our studies reveal a novel means of indirect TPα receptor activation of EGFR 
through the effects of TPα receptor on AREG. 
3.10 Functional status of AREG secreted in response to TPα receptor stimulation 
in the conditioned medium from PC3 transfectants (Immunoblot) 
3.10 A: Effect of AREG on EGFR phosphorylation (Immunoblot) 
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3.10 B: Effect of AREG on EGFR phosphorylation (Immunoblot) 
	  
3.10 C: Effect of AREG on MAPK activation (Immunoblot) 
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3.10 D: Effect of AREG on MAPK activation (Immunoblot) 
 
 
3.10 E: Effect of AREG on EGFR Phosphorylation – Loading control (Immunoblot) 
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Figure 3.10: AREG secreted in response to TPα receptor activation is active and leads to 
EGFR phosphorylation. PC3-TPα and PC3-Neo cells were serum-starved overnight and then 
treated with IBOP only. Conditioned medium was collected and secreted AREG activity post 
TPα stimulation was assayed. PC3 parental cells were serum-starved overnight and pretreated 
with TXA2 antagonist SQ29548 or ETOH for 30 min. These were subsequently treated with the 
conditioned medium collected from PC3 transfectants for 5min or 10min. Cell lysates were 
probed by immunoblot with phospho-specific antibodies for EGFR (A) and ERK1/2 (C). Total 
EGFR (B) and ERK1/2 (D) were used as loading controls for p-EGFR and p-ERK respectively. 
Actin served as a protein loading control (E). AREG in the conditioned medium from PC3-TPα 
cells stimulated increased phosphorylation of EGFR at pY1068 and ERK1/2 when compared to 
the conditioned medium from PC3-Neo cells. These findings indicate that AREG produced in 
response to activation of TPα is functional through binding of EGFR leading to its 
phosphorylation and activation of MAPK pathways. Immunoblotting for each protein was 
performed at least twice using independently prepared lysates, and representative data from 
one such experiment are shown. 
 
Activation of TPα signaling promotes overexpression of EGFR in PC3 cells over 
expressing TPα: 
  After observing the relationship between TPα signaling and increased 
AREG expression at the level of both protein and mRNA, we looked to see whether TPα 
affected the expression of EGFR itself from PC3-TPα and PC3-Neo cells that were 
treated with ETOH, IBOP and SQ29548. After 16 hr, cells were trypsinized and cell 
pellets were divided into two tubes for protein and cDNA analysis respectively. Real-
time PCR and immunoblot analyses revealed that EGFR mRNA and protein expression 
was significantly elevated in PC3-TPα cells in response to IBOP when compared to the 
vector control cells (PC3-Neo) (Figures 3.11 A, B). Pretreatment with TXA2 antagonist 
SQ29548 before addition of IBOP reduced EGFR expression to the level in untreated 
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cells, thereby confirming that TPα signaling also regulates EGFR expression in addition 
to AREG (Figures 3.11 A, B).  
 We opted to corroborate the findings from PC3 transfectants by examining 
parental cells that have naturally elevated levels of TPα. These were treated with either 
ETOH (Vehicle) or TXA2 agonist IBOP or TXA2 antagonist SQ29548 for 16hr. DU145 
cells stimulated with IBOP had a significant increase in EGFR mRNA (Figure 3.11C) 
and protein levels (Figure 3.11D) compared to ETOH treated cells. Pretreatment with 
SQ29548 prior to addition of IBOP reduced EGFR expression back to levels achieved 
with ETOH alone (Fig 3.11 C, D). Collectively these data reveal that TPα activation with 
IBOP in PC3-TPα transfectants as well as in parental DU145 cells stimulated AREG 
production, and also its cognate receptor, EGFR. This demonstrates for the first time 
that signaling events of the two receptors are coupled in prostate cancer. 
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3.11 B: Effect of TPα stimulation by IBOP on EGFR (protein) expression in                       
PC3 transfectants (Immunoblot) 
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3.11 D: Effect of TPα stimulation by IBOP on EGFR (protein) expression in                       
DU145 cells (Immunoblot) 
           
 
Figure 3.11: Activation of TPα in PC3 cells over expressing TPα resulted in an increase of 
EGFR. PC3-TPα, PC3-Neo and DU145 cells were serum starved overnight and were either 
treated with ETOH, IBOP (50 nM) only or pretreated with SQ29548 (10 μM) for 30m before 
addition of IBOP for 16 hr. After treatment, cells were trypsinized, centrifuged and cell pellets 
were divided into two tubes for protein and cDNA analysis respectively. Data from Real-time 
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PCR reflects an increase in expression of EGFR mRNA expression in PC3-TPα cells treated 
with IBOP (A) when compared with ETOH or SQ29548 treated cells. Results from the 
immunoblotting suggest that activation of TPα by TXA2 mimetic IBOP in PC3-TPα cells resulted 
in an increase of EGFR (B) Similar results were obtained with DU145 cells that have higher 
endogenous TPα expression (C, D). Immunoblotting for each protein was performed at least 
three times using independently prepared lysates, and representative data from one such 
experiment is shown. Real-time PCR Values expressed represent the mean fold change ± SEM, 
compared to ETOH treated vector control cells and is derived from three experiments 
normalized in each case to GAPDH gene expression. Similar results were observed in a further 
two independent experiments. 
 
Activation of TPα signaling had little effect on expression of ErbB2, ErbB3 and 
ErbB4 in PC3 cells over expressing TPα 
 As EGFR was over expressed in response to TPα stimulation, we then sought to 
determine whether TPα could affect a change in expression of other EGFR family 
members such as ErbB2 (HER2), ErbB3 (HER3) and ErbB4 (HER4) that can indeed 
dimerize with EGFR. PC3 transfectants cells were serum-starved overnight and treated 
with ETOH, IBOP alone or pretreated with SQ29548 for 30 min followed by addition of 
IBOP for 16 hr.  After treatment, cells were trypsinized, centrifuged and cell pellets were 
divided into two tubes for protein and cDNA analysis respectively. Real-time PCR 
(Figures 3.12 A, B, C) and Immunoblot analyses (Figure 3.12 D) revealed that there 
was very little effect on ErbB2, ErbB3 and ErbB4 mRNA and protein expression in PC3-
TPα cells in response to IBOP when compared to the vector control cells (PC3-Neo). 
Pretreatment with TXA2 antagonist SQ29548 before addition of IBOP, did not affect the 
expression of EGFR family members (Figures 3.12A, B, C, D). These studies clearly 
demonstrate that TPα activation with IBOP in PC3-TPα transfectants resulted in 
increased expression of EGFR but not other EGFR family members. 
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3.12 D: Immunoblot: Effect of IBOP on ErbB2, ErbB3, ErbB4 expression                            
in PC3 transfectants 
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Figure 3.12: TPα activation in PC3-TPα transfectants had little effect on expression of 
other EGFR Family members, ErbB2, ErbB3 and ErbB4. PC3-TPα and PC3-Neo cells were 
serum-starved overnight and were treated either with ETOH, IBOP (50 nM), only or pretreated 
with SQ29548 (10 µM) for 30m before addition of IBOP for 16 hr. After treatment, cells were 
trypsinized, centrifuged and cell pellets were divided into two tubes for both protein and total 
RNA isolation. Real-time PCR data indicate that activation of TPα by IBOP in PC3-TPα cells 
had little effect on expression of ErbB2, ErbB3 and ErbB4 mRNA (A, B, C) when compared with 
ETOH or SQ29548-treated cells. Additionally results from the immunoblotting suggest that 
activation of TPα by TXA2 mimetic IBOP in PC3-TPα cells had little effect on expression of other 
EGFR family members, ErbB2, ErbB3 and ErbB4 (D). Real-time PCR Values expressed 
represent the mean fold change ± SEM, compared to vector control cells and is derived from 
three experiments normalized in each case to GAPDH gene expression. Similar results were 
observed in a further two independent experiments. Immunoblotting for each protein was 
performed at least twice using independently prepared lysates, and representative data from 
one such experiment are shown. 
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EGFR upregulated as a result of TPα activation is functional and actively signals 
in PC3 transfectant cells: 
 As our data from real-time PCR and Immunoblot showed that PC3 cells do 
express EGFR but exhibited differential expression of other EGFR family members in 
PC3 transfectant cells. Therefore, we wanted to confirm, whether the EGFR expressed 
in response to TPα stimulation in PC3 transfectants cells was functional. To test the 
functionality of EGFR produced by PC3-TPα transfectants in response to TPα 
stimulation, we treated PC3-Neo and PC3-TPα cells with either EGF or vehicle (PBS) 
for 5 min. Total protein was harvested from these cells and assayed for the levels of p-
EGFR, EGFR, p-ERK and ERK by Western blotting (Figure 3.13).  
 As evident on Figure 3.13, treatment of PC3-Neo and PC3-TPα cells with EGF 
resulted in increased phosphorylation of EGFR at pY1068, which is an indication of 
ligand dependent phosphorylation and a functional receptor (Figure 3.13).  Furthermore, 
signaling pathways that are downstream of EGFR such as MAP kinase were activated 
as evident by phosphorylation of ERK1/2 (Figure 3.13).  
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3.13 Functional status of EGFR expressed in PC3 transfectants (Immunoblot)	  
	  	  	  	   	  
	  	  	  	   	  
  
77 
	  
Figure 3.13: Add-back experiment proving that EGFR expressed in PC3 transfectants is 
functional. PC3-TPα and PC3-Neo cells were serum-starved overnight and then treated with 
either PBS (vehicle) or EGF for 5min and cells were lysed, and immunoblotted with phospho-
specific antibodies for EGFR (A) and ERK1/2 (C). Total EGFR (B) and ERK1/2 (D) were used 
as a loading control for p-EGFR and pERK1/2 respectively.  Actin (E) served as a protein 
loading control. Our data indicate that EGF treated PC3-Neo and PC3-TPα cells showed 
increased phosphorylation of EGFR and ERK1/2 concluding that EGFR expressed in both PC3-
Neo and PC3-TPα cells is functional. Immunoblotting for each protein was performed at least 
twice using independently prepared lysates, and representative data from one such experiment 
are shown. 
 
Upregulation of AREG by TPα is not dependent on the PKA pathway: 
 The molecular mechanisms involved in the regulation of AREG expression by 
TPα receptor are largely unknown. Our studies show that activation of TPα by IBOP in 
PC3-TPα cells results in increased levels of the second messenger cAMP (Figure 3.4). 
Recent studies have shown that the cAMP pathway can induce AREG in T cells as well 
as in cells of nonlymphoid origin such as H295R (adrenal) and MCF-7 cells (breast 
cancer) [160]. As it is known that one of the downstream targets of cAMP is PKA, we 
wondered whether PKA might be involved in the expression of AREG.  
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 To look into the role of PKA and EGFR in TPα mediated AREG expression, we 
pretreated PC3-TPα and PC3-Neo cells with PKA inhibitor H89 (20 μM) for 30 min 
before incubation with TXA2 agonist IBOP for 18 hr. Following incubation, total RNA was 
isolated from these cells and processed for Real-time PCR analysis of AREG mRNA 
expression. Treatment with the PKA inhibitor H89 had no effect on AREG expression 
mediated by activation of TPα receptor (Figure 3.14). This suggests that upregulation of 
AREG by TPα is not dependent on the PKA pathway. 
	  
 
 
Figure 3.14: Upregulation of AREG by TPα is not dependent on the PKA pathway. PC3-
TPα and PC3-Neo transfectants were serum-starved overnight and were treated either with 
ETOH, IBOP (50 nM) only, or pretreated with SQ29548 (10 µM) and H89 before addition of 
IBOP for 16 hr. Data from Real-time PCR confirms that PKA inhibitor H89 had no effect on 
AREG expression mediated by activation of TPα receptor in PC3-TPα cells when compared to 
IBOP treated cells alone. Values expressed represent the mean fold change ± SEM, compared 
to ETOH treated vector control cells and is derived from three experiments normalized in each 
case to GAPDH gene expression. Similar results were observed in a further two independent 
experiments. 
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Upregulation of AREG by TPα is dependent on the AMPK pathway. 
 Though studies have shown that AREG can be induced by the cAMP pathway in 
in T cells as well as in cells of nonlymphoid origin such as H295R (adrenal) and MCF-7 
cells (breast cancer) [160], our Real-time PCR data nonetheless showed that 
pretreatment of PC3 transfectant cells with PKA inhibitor (downstream mediator of 
cAMP) had no effect on expression of AREG, which suggested an alternate pathway 
involving cAMP [160]. We wondered whether AMP-activated protein kinase (AMPK), an 
alternate cAMP-signaling pathway is involved in the overexpression of AREG mediated 
by stimulation of TPα receptor. As we have previously shown that activation of TPα 
does increase cAMP levels, the relationship between thromboxane signaling, AMPK 
and AREG was studied in TPα overexpressing PC3 cells. AMPK is a sensor for 
changes in cellular energy state and is activated by an increase in the intracellular AMP-
to-ATP ratios in response to various stresses such as hypoxia, oxidative stress and 
glucose deprivation [190-194]. Activation of AMPK requires phosphorylation of Thr172 
in the activation loop of the α subunit by at least 2 upstream kinases, LKB1 and 
Ca2+/calmodulin-dependent kinase kinase (CaMKK)-β [190-194].  
 TPα activation increases cAMP levels, as well as intracellular Ca2+ concentration. 
Therefore we investigated the role of AMPK in TPα mediated AREG expression. 
Previous studies by Zhang et al. had shown that TP activates the AMPK in vascular 
smooth muscle cells via hydrogen peroxide [190].  
 Apart from cAMP being a regulator of AREG expression, studies have shown 
that AREG also can be regulated by the EGFR itself and activation of EGFR leads to 
AREG expression in several cell types [155, 157, 160, 166]. As it is known that EGFR 
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can directly regulate AREG through EGFR-AREG autocrine loop, we questioned 
whether this might be true in TPα mediated AREG upregulation [155] 
  To investigate whether TPα mediates AREG upregulation via the AMPK 
pathway and to identify the role-played by EGFR in the expression of AREG, we 
pretreated the PC3-TPα and PC3-Neo cells with the AMPK inhibitor Compound-C (20 
μM) and EGFR inhibitors Gefitinib (20 μM) or AG1478 (5 μM) for 30 min before 
incubation with TXA2 agonist IBOP for 18hrs. Gefitinib or AG1478 is an EGFR inhibitor 
that binds to the tyrosine kinase domain and inhibits downstream EGFR signaling. 
Following incubation, total RNA was isolated from these cells converted to cDNA and 
Real-time PCR was done for AREG mRNA expression. The amount of AREG transcript 
was estimated based on the Relative quantification method. Treatment with the AMPK 
inhibitor Compound-C in PC3-TPα cells led to an decrease in the level of AREG as 
shown in Figure 3.15A to the levels comparable to ETOH or SQ29548 treated cells. 
This suggests that TPα upregulates AREG mRNA levels through cAMP by stimulating 
the AMPK pathway (Figure 3.15A). 
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Figure 3.15: Upregulation of AREG by TPα is dependent on AMPK pathway. PC3-TPα and 
PC3-Neo transfectants were serum starved overnight and were either treated with ETOH, IBOP 
50nM only or pretreated with SQ29548 (10 µM), Gefitinib (20 μM), AG1478 (5 μM) and 
Compound-C (20 µM) for 30 min before incubation with IBOP for 18 hr. AMPK inhibitor 
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Compound-C strongly affects AREG expression mediated by TPα in PC3-TPα cells (A). EGFR 
inhibitors, Gefitinib and AG1478 reduced expression of AREG, mediated by TPα in PC3-TPα 
cells to a lesser extent than compound-C (A). Values expressed represent the mean fold 
change ± SEM, compared to vehicle treated vector control and is derived from three 
experiments normalized in each case to GAPDH gene expression. Data from ELISA supports 
the Real-time PCR data, that inhibition of the AMPK pathway reduces levels of AREG 
expression mediated by TPα activation (B). Similar results were observed in a further two 
independent experiments. The ELISA results shown are mean ± standard deviation of 
triplicate wells, *p <0.05, **p <0.01; Student’s t test. This experiment was repeated at least three 
times with similar results. 
 
 To verify our findings from Real-time PCR at the protein level, conditioned media 
was collected from PC3-TPα and PC3-Neo cells treated with AMPK inhibitor or EGFR 
inhibitors and the levels of AREG were assayed by ELISA and normalized to cell 
number. We observed that, Compound-C decreased AREG secretion from PC3-TPα 
cells when compared to IBOP treated cells (Fig 3.15B). Also treatment with EGFR 
inhibitors had a partial inhibition on expression of AREG mediated by TPα when 
compared with AMPK inhibitor (Fig 3.15B). The reduction of AREG secretion in PC3-
TPα overexpressing cells upon treatment with AMPK inhibitor suggests that the AMPK 
pathway is required for AREG secretion in these cells (Fig 3.15B). From these 
experiments, it is evident that AMPK pathway plays a key role in IBOP mediated 
increase in AREG secretion in the TPα overexpressing cells. 
Activation of TPα signaling results in increased PCa cell invasion. 
 To determine whether TPα activity in PC3 cells translates to a more invasive 
phenotype and AREG does play a role in it, a modified Boyden chamber assay was 
performed where transwell chambers were coated with Matrigel, and PC3-TPα or PC3-
Neo cells were treated with either ETOH (Vehicle), IBOP (agonist), or SQ29548 
(antagonist). Of all the treatments, only IBOP increased the invasiveness PC3-TPα cells 
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(Figures 3.16A, 3.16B). Similar results were obtained with DU145 cells that have higher 
endogenous TPα levels. Treatment of DU145 cells with IBOP also increased the 
invasive capacity of the cells when compared to treatment with either ETOH or 
pretreatment with the antagonist SQ29548 (Figure 3.16C). Invasiveness of PC3-TPα 
and PC3-Neo cells were similar in response to 5% FBS stimulation. 
 Studies have shown that EGFR signaling pathway plays an important role in cell 
migration and invasion [195, 196], we wondered whether AREG or EGFR might be 
involved in increasing the invasive capacity of the cells mediated by TPα. Over 
expression of AREG mediated by TPα in PCa cells can then activate EGFR and then 
activate signaling pathways that result in increasing the invasive nature of these cells. 
To study whether AREG or EGFR has a role to play in it, we pretreated PC3-TPα and 
PC3-Neo cells with EGFR inhibitor gefitinib (25 μM) or AMPK inhibitor-Compound-C (20 
μM) for 30min, before incubation with IBOP for 18 hr and cells were fixed and pictures 
of invasive cells were taken with a Nikon TE200 inverted microscope (Figure 3.16A, C,). 
Gefitinib is an EGFR inhibitor that binds to its tyrosine kinase domain and inhibits 
signaling through the EGFR pathway and Compound-C is an AMPK inhibitor. Binding of 
gefitinib to EGFR also will prevent AREG to activate EGFR and thereby affecting its role 
in cellular invasion whereas AMPK inhibitor should affect the overexpression of AREG 
mediated by TPα receptor. Treatment with Gefitinib or AMPK inhibitor did reduce the 
invasiveness of these cells, induced by IBOP, indicating that EGFR signaling is involved 
in TPα mediated invasion (Figure 3.16A, B, C, D). Similar results were obtained with 
DU145 cells that have higher endogenous TPα levels when treated with EGFR inhibitor 
gefitinib or AMPK inhibitor (Figure 3.16E, F). 
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3.16 A: Effect of EGFR and AMPK inhibitors on TPα mediated cell invasion in                 
PC3-TPα cells (Modified Boyden chamber assay) 
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3.16 C: Effect of EGFR and AMPK inhibitors on TPα mediated cell invasion in                 
PC3-Neo cells (Modified Boyden chamber assay) 
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3.16 E: Effect of EGFR and AMPK inhibitors on TPα mediated cell invasion in             
parental DU145 cells (Modified Boyden chamber assay) 
 
 
 
 
Figure 3.16: Activation of TPα signaling by IBOP stimulation results in increased 
invasiveness of PCa. Modified Boyden chamber assay was done where transwell chambers 
were coated with matrigel and PC3-TPα and PC3-Neo cells that were serum starved overnight 
and were either treated with ETOH, IBOP (50 nM) only or pretreated with SQ29548 (10 μM) 
Gefitinib (20 μM) or AMPK inhibitor Compound-C (20 μM), before IBOP was added to the 
chamber. After 16 hr of treatment, cells that invaded to the bottom of transwell chamber were 
fixed and photographed. IBOP treatment stimulated the invasive capability of PC3-TPα cells in 
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the in vitro invasion assay, whereas the vehicle, antagonist, Gefitinib, Compound-C reduced the 
invasive capability of PC3-TPα cells (A, B). Similar results were obtained with DU145 cells that 
have higher endogenous TPα expression (C). Representative phase contrast microscope 
pictures are shown in correlation with the invasion assay from three independent experiments. It 
was also quantified by counting the number of cells that invaded to the lower side of the filter in 
three representative fields in each independent experiment.  
 
TPα signaling results in larger tumors in a mouse model:  
  To examine the physiological relevance of increased colony formation and 
invasion brought on by TP-α expression and signaling in PCa cells, we introduced PC3-
TPα or PC3-Neo cells into athymic mice in an established subcutaneous (s.c.) xenograft 
tumor model to assess tumor growth in vivo. Prostate cancer cell proliferation in vitro 
was largely comparable between PC3-TPα and PC3-Neo cells. This suggested that 
PC3-TPα transfectants did not have a growth advantage over PC3-Neo cells in vitro 
(Data not shown).  
 However mice that received PC3-TPα cells formed larger tumors compared to 
mice injected with PC3-Neo cells, indicating that TPα transfected PC3 cells had an in 
vivo growth advantage compared to Neo controls. (Figures 3.17, 3.18 A, B). Weekly 
measurements over a 7-8 week period, revealed that tumors originating from PC3-TPα 
cells injected into nude mice grew faster compared to PC3-Neo mice. (Figure 3.17)  
After 7-8 weeks, mice were sacrificed as per the animal protocol, and tumors resected 
from the mice receiving PC3-TPα were larger and found to weigh approximately twice 
that of tumors originating from PC3-Neo-injected mice. (Figure 3.18 A, B, C, D) 
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Figure 3.17: Mice bearing PC3-TPα cells showed greater tumor growth compared to the 
control group. Increases in tumor growth in mice injected with PC3-TPα transfectants were 
observed compared to PC3-Neo controls. Tumor growth was plotted for 7-8 weeks and a growth  
curve was obtained. 
 
3.18: Size and weight Comparison of tumors originating from PC3 vector controls 
and PC3 cells overexpressing TPα 
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Figure 3.18: Size and weight Comparison of tumors originating from PC3 vector controls 
and PC3 cells overexpressing TPα. PC3 cells over expressing TPα yielded larger tumors      
in vivo compared to PC3 parental cells carrying the expression vector alone. Mice (n=6) 
receiving PC3-TPα (A) and mice (n=6) receiving PC3-Neo (B) were photographed on Day-56 
after they were sacrificed. Tumors excised from mice injected with PC3-TPα cells were larger in 
size compared to the PC3-Neo controls (C). Tumors excised from mice injected with PC3-TPα 
cells displayed twice the weight (D) compared to the PC3-Neo controls. Weight of the mice 
displayed on the graph is average weight of each group of mice (n=6) (D). 
 
Angiogenesis plays an important role in tumor growth and is considered a key 
step in tumor development. We found significant vascularization in tumors derived from 
TPα transfected PC3 cells, whereas the PC3-Neo control tumors showed little vessel 
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penetration. (Figure 3.19A)  Paraffin-embedded tumor sections from mouse xenografts 
of PC3-TPα cells or PC3-Neo cells were immunostained using antibodies specific for 
CD31, which is an endothelial cell marker (Fig 3.19C). Real-time PCR on the cDNA 
from tumors also confirmed the increased expression of CD31 in PC3-TPα tumors 
compared to controls (Fig 3.19B).  
 To confirm whether increase in proliferation due to EGFR signaling was 
responsible for increased tumor size seen in PC3-TPα mice, Paraffin-embedded tumor 
sections from mouse xenografts of PC3-TPα cells or PC3-Neo cells were 
immunostained using antibodies specific for KI67, which is an proliferation marker (Fig 
3.19C). Immunohistochemistry analysis of the tumors sections also confirmed the 
stronger staining for Ki67 in PC3-TPα tumors compared to controls (Fig 3.19D). 
Our in vitro data revealed that IBOP activation of TPα enhanced cellular AREG 
and EGFR levels.  Therefore, mouse tumors were examined for expression of these 
downstream targets.  Analysis of cDNA generated from the tumor samples revealed that 
EGFR, as well as AREG, VEGF and IL6 were in fact over expressed in tumors 
originating from PC3-TPα transfectants (Figure. 3.20B). Furthermore, it was confirmed 
that PC3-TPα cells maintained elevated expression levels of TPα compared to PC3-
Neo controls over the duration of the six week in vivo growth experiment. (Figure. 
3.20A) 
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Figure 3.19: Increased neo vascularization and proliferation was observed in tumors from 
mice harboring PC3-TPα cells compared to those given vector controls. Comparison of 
vessel density of tumors ex vivo from PC3-TPα mice compared to control mice (A). Presence of 
CD31, a prominent angiogenesis marker, was increased at the mRNA levels in mice injected 
with PC3-TPα compared to PC3-Neo controls (B). Immunohistochemical analysis for CD31, an 
endothelial marker, showed that sections from PC3-TPα tumors were strongly positive for CD31 
(C). Arrowheads show the staining regions for CD31. Immunohistochemical analysis for Ki67, a 
proliferation marker, showed that sections from PC3-TPα tumors were strongly positive for Ki67 
(D). Arrowheads show the staining regions for Ki67. 
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Figure 3.20: Increased expression of downstream target genes known to affect tumor 
growth. In order to determine whether increased tumor growth in PC3-TPα, injected mice is due 
to increased expression of either pro angiogenic factors or growth factors, RNA isolated from 
mouse tumors was converted to cDNA and gene expression was quantified using Real-time 
PCR. PC3-TPα transfectants maintained high TPα receptor levels in mouse tumors for the 
duration of the study (A). Elevated TPα levels were associated with increased expression of 
target genes such as AREG, EGFR, VEGF-A and IL6 (B). Values expressed represent the 
mean fold change ± SEM, compared to vector control mice and is derived from three 
experiments normalized in each case to GAPDH gene expression. Similar results were 
observed in a further two independent experiments. 
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Activation of TPα also promotes increased angiogenesis in a mouse model: 
 Increased neo vascularization was seen in PC3-TPα tumors as well as increased 
expression of VEGF-A mRNA. This implied TPα might also lead to tumor growth by 
playing a role in angiogenesis. 
 The increased angiogenicity due to TPα mediated VEGF expression in PC3-TPα 
tumors was confirmed by the Matrigel implantation assay in an in vivo xenograft mouse 
model. As shown in Fig. 3.21, within 12 days, TPα transfected PC3 cells (PC3-TPα) in 
matrigel induced increased angiogenesis, indicated by the accumulation of blood in the 
gel, compared to the neo control (PC3-Neo). The results clearly illustrate that the TPα 
transfected PC3 cells are more angiogenic than their neo controls. 
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Figure 3.21: Induction of angiogenesis in Matrigel by TPα transfectants: PC3-TPα cells or 
PC3-Neo control cells (2xI06) were mixed with matrigel BME and injected s.c. into the right flank 
of 4-6-week-old male SCID mice (n=6). In Mice injected with PC3-TPα cells mixed with Cultrex 
BME, there was increased vessel penetration into the gel and considerable blood accumulation 
was observed (A). In contrast, mice injected with PC3-Neo cells mixed with Matrigel BME, the 
vessel penetration into the gel was minimal, with little blood accumulation (B).  
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Chapter-4: Summary and Discussion: 
 
Development of prostate cancer (PCa) is a multistep process. A key step in this 
process is the overexpression of growth factors and their receptors that results in the 
progression of normal prostate epithelial cells to a hyper proliferative cancer cell [171, 
172]. Changes in gene expression of growth factors and their corresponding receptors 
in epithelial and stromal cells during the different developmental stages of prostate 
cancer contribute to enhanced tumor cell growth, survival, migration and invasiveness 
[171, 172]. Among these, the ErbB family of receptors and their ligands, the EGF family 
of peptide growth factors, has a central role in the pathogenesis and progression of 
different carcinoma types [141, 144, 146, 150]. In particular, epidermal growth factor 
receptor (EGFR) signaling has been associated with a wide variety of tumors and 
causes PCa to progress by becoming invasive and metastatic [170, 171] [173, 174].  
 In this study, we report for the first time that activation of TPα signaling can lead to 
over expression of AREG, a ligand of EGFR in prostate cancer cells. Our data also 
indicate that activation of TPα not only upregulates AREG expression, but also 
increases the expression of its cognate receptor EGFR. We also have demonstrated 
that of the two TP receptor isoforms, only TPα receptor is expressed in PCa cells and 
tissues.  These findings suggest an alternate mechanism by which TPα can activate 
EGFR signaling pathways leading to increased tumor growth. The experimental 
evidence from this study has revealed molecular mechanisms underlying the enhanced 
expression of AREG in prostate cancer. Our data indicate that the AMPK pathway plays 
an important role in the expression of AREG mediated by TPα in PCa cells. 
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 Recent studies have shown that GPCRs are able to utilize the EGFR as a 
downstream signaling partner in the generation of growth signals that might play an 
important role in various cancers [124, 125, 128]. Studies have identified that EGFR as 
an essential link in the GPCR-mediated activation of downstream signaling pathways 
such as MAPK pathways in several cell types treated with the GPCR agonists [128, 
197-199]. The TP receptor also uses EGFR as an essential link in the activation of 
downstream signaling pathways. Two mechanisms i.e. ligand-dependent (shedding of 
HB-EGF by MMPs) or ligand-independent (Src kinase mediated) have been proposed 
that involve transactivation of EGFR by phosphorylation that leads to activation of 
downstream signaling pathways [127] [126]. These models were established in HEK 
cells over-expressing TP receptor-EGFR crosstalk has been established using HEK 
cells overexpressing TP receptor and they have not examined in cancer cells. Therefore 
alternate pathways involved in activation of EGFR by TP receptor are possible.  
In this study we have proposed a novel mechanism by which EGFR can be 
activated in PCa cells through GPCR. Our data show for the first time that increased 
expression of AREG in response to TP stimulation by its agonist can lead to EGFR 
activation in PCa cells.  Our data also confirm that increased levels of AREG, seen in 
response to stimulation of TPα, result in functional binding to EGFR, leading to EGFR 
phosphorylation and activation of downstream MAPK pathways. Elevated AREG could 
then lead to constitutive EGFR signaling and activation of downstream signaling 
pathways involved in cellular proliferation, cell migration, cell survival, and 
angiogenesis. Overexpression of AREG has been reported in both androgen dependent 
and independent prostate cell lines as well as tissues. However the specific pathways 
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leading to AREG expression have not yet been elucidated [157, 158, 175]. Our study 
sheds light on a novel pathway, where we found that activation of TPα led to increased 
expression of AREG. This presents a mechanistic explanation for those findings, as we 
also determined that TPα is over-expressed in PCa cell lines.  
 We discovered that TPα activation also led to over expression of EGFR. It is 
known that AREG acts exclusively through EGFR, where it binds EGFR with a lower 
affinity than EGF, and induces receptor autophosphorylation and downstream activation 
of the ERK signaling cascade [156, 158]. One of the most studied receptor tyrosine 
kinases i.e. EGFR and its signaling pathway is central to both physiological and 
pathophysiological process [139, 140, 143, 144, 150].   Over-expression of EGFR or up-
regulation of its signaling pathway has been associated with several cancers and has 
led to uncontrolled cellular proliferation and autocrine stimulation of tumors producing 
their own growth factors [141, 146, 149, 150, 200]. The enhanced expression of EGFR 
and its ligands, EGF, TGF-α, HB-EGF and AREG, has been reported to correlate with 
high grades of PCa malignancies [158, 174].  
  The mechanisms responsible for AREG upregulation in transformed cells 
are not fully understood and might vary from one tumor subtype to another. Recent 
studies have shown that AREG can be induced by cAMP pathway in various cell types 
[160]. A cAMP-responsive element (CRE) has been described in the AREG promoter 
and expression of AREG is regulated by cAMP [160, 161]. AREG can also be regulated 
by EGFR itself, and activation of EGFR leads to AREG expression in several cell types 
[155, 157, 166, 168]. We investigated and determined that activation of TPα clearly 
increases the cAMP levels in PCa cell lines. These findings and other studies point to a 
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possible role for cAMP and EGFR in over expression of AREG that is induced by TPα 
signaling. 
 As our data indicate, blocking EGFR activation with EGFR inhibitors (Gefitinib, 
AG1478) actually reduced AREG levels in TPα over-expressing cells, that TPα 
upregulates AREG mRNA by direct activation of EGFR via EGFR phosphorylation. 
Inhibition of PKA (downstream mediator of cAMP) prior to EGFR inhibition did not affect 
the expression of AREG. The possibility of an alternate pathway involving cAMP [160] 
led us to consider whether the AMPK pathway was involved. The thromboxane receptor 
reportedly can activate the AMP-activated protein kinase in vascular smooth muscle 
cells via hydrogen peroxide [190]. Treatment with the AMPK inhibitor (Compound-C) led 
to a decrease in AREG both at the level of mRNA and protein (Figure 3.15). Therefore 
we have identified the AMPK pathway as the key signaling pathway triggered by TPα to 
increase AREG expression in human prostate cancer cells.  
 Aberrant EGFR and AREG signaling has been recognized to affect cellular 
proliferation, cell migration, cell survival, and angiogenesis [141, 144, 146, 150]. Many 
of these key steps in cancer progression are also regulated by TP receptor. Previous 
studies from our lab have shown that activation of TPα receptor by IBOP induces cell 
motility through the Rho-A pathway [101]. As AREG had been shown to upregulate 
several genes known to be involved in motility and invasion in breast cancer cells [155, 
156, 168], we investigated whether TPα-AREG-EGFR signaling plays a role in PCa cell 
invasion. Our invasion assays showed that TPα does in fact play a role in cell invasion, 
and is mediated by EGFR signaling. Our data also confirm that increased expression of 
AREG induced by TPα receptor promoted cell invasion, as blocking AREG expression 
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with AMPK inhibitors reduced invasion. These data indicate that PCa cells expressing 
AREG in response to TPα receptor stimulation require autocrine signaling through 
EGFR for cell invasion to occur. 
 Activation of TPα receptor in PC3-TPα cells by IBOP promoted increased 
expression of growth factors such as AREG and its receptor EGFR thereby playing a 
role in tumor growth. Using a xenograft mouse model, we demonstrated that TPα 
transfected PC3 cells formed larger tumors than vector controls, and that the increased 
tumor volume was positively correlated with enhanced tumor angiogenesis. Tai et al., 
have shown that overexpression of TPα in A549 lung cancer cells also led to enhanced 
tumor angiogenesis and growth in a xenograft animal model [201]. Taken together, 
these studies suggest that expression of TPα in cancer cells can enhance their 
angiogenic potential through expression of growth factors leading to tumor growth. We 
found significant vascularization in tumors derived from PC3-TPα cells, compared to 
PC3-Neo tumors. Formalin fixed paraffin-embedded tumor sections from these mice 
showed very strong CD31 staining. Analysis of tumors from PC3-TPα mice by real-time 
PCR showed increased expression of pro-angiogenic growth factors and cytokines such 
VEGF and IL6.  
 Angiogenesis is a multistep process that requires the concerted action of 
numerous growth factors. VEGF is an important angiogenic factor that had been 
correlated with poor prognosis and improved survival of solid tumors. Expression and 
secretion of VEGF is triggered by a vast multitude of factors and signaling pathways in 
cancer cells [202, 203].  In solid tumors, the VEGF and EGFR pathways are linked with 
respect to angiogenesis [204, 205]. EGFR ligands such as EGF and TGF-α can induce 
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VEGF expression via activation of EGFR in cell culture models and have proangiogenic 
properties [204, 205]. It is likely that the EGFR pathway modulates angiogenesis by up-
regulating VEGF or other key mediators in the angiogenic process [206]. The increased 
angiogenicity due to TPα mediated VEGF expression in PC3-TPα tumors was 
confirmed by the Matrigel implantation assay in an in vivo xenograft mice model 
indicating that increased EGFR signaling mediated by TPα to be responsible for it.  
 In this study, we identified which TP receptor isoform is predominantly expressed 
in PCa cells and tissues. Though the existence of two TP isoforms was described as 
early as 1994, most of the earlier studies on TP did not distinguish the functional roles 
between the two isoforms and it was assumed that most of the functional effects of TP 
to be mediated by TPα. Recent findings though provide a novel role for TPβ in bladder 
cancer progression [99]. Until now the expression status of TP isoforms was largely 
uncharacterized in prostate cancer cells and tissues. Identification of the active isoform 
in prostate cancer will help us to design isoform-specific antagonists or inhibitors that 
uniquely target this pathway for greater therapeutic impact. 
One of the technical challenges in working with TP isoforms is the lack of 
isoform-specific antibodies. The only difference between TPα and TPβ is that TPα has a 
shorter C-terminal cytoplasmic tail than the TPβ isoform (15 versus 79 residues) [52-
54]. Currently there are no commercially available antibodies that can discriminate 
these two isoforms. To distinguish them, we designed Taqman gene expression assays 
specific for each TP isoform and were able to differentiate their expression level in PCa 
cells and tissues. Within the detection boundaries of this assay, TPα appeared to be 
solely expressed isoform in PCa cell lines and tissues. We used several approaches 
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(Immunoblot, RT-PCR, Real-time PCR, cAMP enzyme Immunoassay) to look into the 
possible expression of both TP isoforms in PCa, but our data strongly pointed that only 
TPα expression is seen in PCa cells. Data from our tissue array analysis show that TPα 
expression is higher in prostate cancer tissues compared to normal prostate tissues. 
Collectively, the data-mining results and the data from Real-time PCR analysis of 
human tissue arrays make a strong case for the association of TPα expression with the 
aggressiveness and progression of prostate tumors. Previous studies by Bostwick et al. 
were able to conclude that increased expression of AREG might contribute to the 
development of prostatic adenocarcinoma [158].  
 EGFR protein was found by Marks et al. to be frequently expressed in tissue 
from prostate cancer patients undergoing hormone therapy [207].  In 57 of 71 patients 
undergoing hormonal therapy, there was demonstrable EGFR expression by 
immunostaining.  More studies will be needed to focus on the co-expression levels of 
both TPα and AREG in prostate cancer tissues in relation to EGFR so as to determine 
their connectivity.  In gastric cancer cell lines, Cetuximab responsiveness against EGFR 
was associated with AREG levels, and Cetuximab treatment attenuated AREG, while 
EGF elevated AREG.  This implies that the EGFR pathway itself appears to regulate 
AREG[208]. It is known that TPR activation includes the expression of a nuclear 
receptor called Nurr1 that can stimulate proliferation of lung cancer cells [119].  In turn, 
Nurr1 has been shown to regulate pro-inflammatory mediators, including AREG, in 
synovial fibroblasts [209]. As both TPα and AREG are over expressed in PCa tissues, it 
will be interesting if links such as those implied by the Nurr1 studies play a role in TPα-
mediated expression of in human PCa tissues. 
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Conclusion: 
 In summary, our study has identified a novel link between TPα signaling and 
AREG expression in prostate cancer cells. We report for the first time that activation of 
TPα signaling in PCa cells can lead to increased expression of AREG and its receptor 
EGFR, and that AMPK plays an important role in regulation of AREG by TPα. EGFR 
signaling has been recognized to be at the forefront of aberrant signal transduction 
pathways, involved in cellular proliferation, cell migration, cell survival, and 
angiogenesis. Over expression of TPα in PC3 cells can result in increased invasiveness 
of PCa cells, which might be mediated by EGFR signaling pathways.  
 Over expression of TPα in PC3 cells led to increased tumor growth and 
angiogenesis in a xenograft mouse model that is likely associated with increased 
expression of AREG, VEGF and EGFR signaling. We report for the first time that TPα 
mRNA expression is elevated in the prostate cancer tissues and conclude that TPα 
expression in PCa tissues correlates with aggressiveness of the disease.  These 
findings suggest that the functional role of TPα in prostate cancer progression might 
involve increased expression of AREG leading to increased activation of EGFR 
signaling promoting angiogenesis, cell invasion and tumor growth. 
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Project Summary 
	  
Figure 4: Summary of TPα receptor mediated AREG expression and EGFR signaling in 
prostate cancer cells 
 
Future Directions: 
 Recent emphasis in prostate cancer research has been on identification of 
candidate genes that are good prognostic or predictive markers. As defined by Busser 
et al., “Prognostic factors provide information on the outcome of the disease, whereas 
predictive factors are used to prospectively select responsiveness or resistance to a 
specific treatment” [169]. TPα appears to be an ideal candidate to be considered as a 
prognostic marker in prostate cancer. TPα was more highly expressed in aggressive 
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forms of PCa and correlated with Gleason scores. A significant finding from our studies 
was that TPα expression was elevated in GS7 (4+3) compared to GS7 (3+4), which 
suggests that differences in TPα expression exist between primary and secondary 
patterns. Further studies are needed in statistically relevant sample set to see whether 
this can potentially be exploited as a biomarker for discriminating GS7 subtypes when 
making prognostic determinations. 
 Further in vivo studies will clarify the actual role of EGFR and AREG in TPα-
mediated tumor growth. This could be approached by knocking down either AREG or 
EGFR in PC3 cells over expressing TPα, injecting them into mice, and following tumor 
growth. Further elucidation of TPα-mediated pathways that elevate expression of AREG 
and lead to subsequent tumor cell growth will provide insights into the key steps 
involved in prostate cancer progression. Inhibition of growth factors and their receptor 
signaling pathways has proven to be an effective approach to block tumor growth. 
Therefore, inhibition of TPα signaling by antagonists, or prevention of TXA2 synthesis by 
inhibiting TXA2S, may be a novel approach to develop anticancer, anti-angiogenic 
therapy [210]. It remains to be determined if TPα and AREG expression in prostate 
cancer tissue can be correlated to each other.   
  The low cost of aspirin has kept it in the forefront of treatment in cardio 
vascular disorders, whereas TXA2S inhibitors and TXA2 antagonists have not been 
employed for clinical benefits. Conversely, current therapeutic regimens for cancer 
incorporate few agents of the NSAID class, which makes TXA2S/TP antagonism an 
attractive target with potentially significant therapeutic benefit. Moreover, in contrast to 
NSAIDs, TXA2S/TP inhibitors do not interfere with synthesis of other beneficial COX-
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derived anti-tumor products, such as PGI2 [211-216]. Hence, future work should focus 
on the advantages of directly targeting TXA2S and/or developing TP antagonists or 
taking advantage of the anti tumor effects of PGI2. 
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 Thromboxane A2 (TXA2) is a major arachidonic acid metabolite that signals 
through TXA2 receptors (TP) to induce platelet aggregation and smooth muscle 
contraction. TXA2 receptors are expressed as two different isoforms in humans, namely 
TP-alpha (TPα) and TP-beta (TPβ), which have common and distinct signaling 
pathways. Of the two TP receptor isoforms, studies have shown that TPα impacts tumor 
growth and progression of lung cancer. Previously our studies demonstrated that 
activation of Thromboxane receptor by TXA2 agonists could regulate prostate cancer 
(PCa) cell motility and cytoskeletal reorganization through activation of Rho-A. The 
primary objective of this study is to investigate the functional role of TPα in prostate 
cancer progression and metastasis.  
 Our data indicates that of the two TPR isoforms, human PCa cell lines only 
express TPα and that expression of TPα is higher in PCa cells compared to cultured 
normal prostate epithelial cells, such as RWPE1. Furthermore, expression of TPα was 
observed to be higher in clinical PCa specimens when compared with normal tissue, 
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and expression was higher in tumor tissues with Gleason scores of 7 and above. In 
response to the TXA2 mimetic, IBOP, DU145 cells that have higher endogenous levels 
of TPα compared to other cell lines, up regulated expression of the growth factor 
Amphiregulin (AREG) and its receptor EGFR. Introduction of an expression plasmid 
encoding TPα into another PCa cell line, PC3 (PC3-TPα), led to a similar phenotype in 
response to IBOP, thereby confirming a link between TPα and over expression of AREG 
and EGFR.  
 Increase in AREG expression mediated by TPα seems to involve EGFR and 
AMP activated protein kinase (AMPK) signaling pathways. PC3-TPα cells treated with 
IBOP were also highly invasive compared to PC3-Neo cells; this invasiveness mediated 
by TPα was affected by pre treatment with an EGFR inhibitor. In a subcutaneous animal 
model, mice injected with PC3-TPα exhibited greater tumor growth and increased neo 
vascularization compared to mice with PC3-Neo cells. Also when mice was injected with 
PC3-TPα cells and Matrigel BME, increased angiogenesis was observed as indicated 
by the accumulation of blood compared to mice with PC3-Neo cells. Collectively these 
data suggest that activation of TPα receptor in PCa cells increases the level of growth 
factors such as AREG and its receptor EGFR that might be mediated through AMPK, 
thereby implicating TPα in prostate cancer progression.  
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